EP1196584A1 - Tetanus toxin polypeptides - Google Patents
Tetanus toxin polypeptidesInfo
- Publication number
- EP1196584A1 EP1196584A1 EP00940598A EP00940598A EP1196584A1 EP 1196584 A1 EP1196584 A1 EP 1196584A1 EP 00940598 A EP00940598 A EP 00940598A EP 00940598 A EP00940598 A EP 00940598A EP 1196584 A1 EP1196584 A1 EP 1196584A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- fragment
- polypeptide
- binding
- tent
- tetanus toxin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 94
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 87
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 87
- 108010055044 Tetanus Toxin Proteins 0.000 title claims abstract description 80
- 229940118376 tetanus toxin Drugs 0.000 title claims abstract description 80
- 230000027455 binding Effects 0.000 claims abstract description 99
- 239000012634 fragment Substances 0.000 claims abstract description 75
- 150000002270 gangliosides Chemical class 0.000 claims abstract description 62
- 230000002163 immunogen Effects 0.000 claims abstract description 38
- 230000007441 retrograde transport Effects 0.000 claims abstract description 21
- 108010044241 tetanus toxin fragment C Proteins 0.000 claims abstract description 20
- 230000035772 mutation Effects 0.000 claims abstract description 19
- 210000002161 motor neuron Anatomy 0.000 claims abstract description 18
- 230000009467 reduction Effects 0.000 claims abstract description 17
- 230000001095 motoneuron effect Effects 0.000 claims abstract description 8
- 210000004027 cell Anatomy 0.000 claims description 77
- 238000000034 method Methods 0.000 claims description 38
- 108091033319 polynucleotide Proteins 0.000 claims description 36
- 102000040430 polynucleotide Human genes 0.000 claims description 36
- 239000002157 polynucleotide Substances 0.000 claims description 36
- 239000013598 vector Substances 0.000 claims description 36
- 229960005486 vaccine Drugs 0.000 claims description 24
- 239000000203 mixture Substances 0.000 claims description 18
- 238000012217 deletion Methods 0.000 claims description 17
- 230000037430 deletion Effects 0.000 claims description 17
- 241001465754 Metazoa Species 0.000 claims description 14
- 241000193449 Clostridium tetani Species 0.000 claims description 12
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 11
- 208000015181 infectious disease Diseases 0.000 claims description 11
- 241000894006 Bacteria Species 0.000 claims description 10
- 239000003085 diluting agent Substances 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 125000000539 amino acid group Chemical group 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 230000001105 regulatory effect Effects 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 description 58
- 235000018102 proteins Nutrition 0.000 description 50
- 102000004169 proteins and genes Human genes 0.000 description 50
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 41
- 239000002953 phosphate buffered saline Substances 0.000 description 41
- 235000001014 amino acid Nutrition 0.000 description 29
- 150000001413 amino acids Chemical class 0.000 description 26
- 210000002569 neuron Anatomy 0.000 description 17
- 239000002671 adjuvant Substances 0.000 description 12
- 230000002829 reductive effect Effects 0.000 description 12
- 108700012359 toxins Proteins 0.000 description 12
- 239000003053 toxin Substances 0.000 description 11
- 231100000765 toxin Toxicity 0.000 description 11
- 108030001720 Bontoxilysin Proteins 0.000 description 10
- 210000000278 spinal cord Anatomy 0.000 description 10
- 238000005406 washing Methods 0.000 description 10
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 9
- 241000588724 Escherichia coli Species 0.000 description 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 8
- 108020001507 fusion proteins Proteins 0.000 description 8
- 102000037865 fusion proteins Human genes 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 150000007523 nucleic acids Chemical group 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 241000283973 Oryctolagus cuniculus Species 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 239000000427 antigen Substances 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 102000039446 nucleic acids Human genes 0.000 description 7
- 108020004707 nucleic acids Proteins 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 238000006467 substitution reaction Methods 0.000 description 7
- NVNPEYQWKCQBBU-ADMXJUBYSA-N (2r,4s,5r,6r)-2-[(2s,3s,4r,5r,6s)-2-[(2r,3s,4s,5s,6s)-3-acetamido-2-[(2s,3r,4s,5s,6r)-4-[(2r,4s,5r,6r)-5-amino-2-carboxy-4-hydroxy-6-(1,2,3-trihydroxypropyl)oxan-2-yl]oxy-6-[(2r,3s,4r,5r,6r)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(e)-3-hydroxy-1-(octadecanoyl Chemical compound O[C@@H]1[C@@H](O)[C@H](OC(CNC(=O)CCCCCCCCCCCCCCCCC)C(O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@]2(O[C@H]([C@H](N)[C@@H](O)C2)C(O)C(O)CO)C(O)=O)[C@H](O[C@@H]2[C@H]([C@H](O[C@@H]3[C@H]([C@H](O[C@@]4(O[C@H]([C@H](N)[C@@H](O)C4)C(O)C(O)O[C@@]4(O[C@H]([C@H](N)[C@@H](O)C4)C(O)C(O)CO)C(O)=O)C(O)=O)[C@H](O)[C@H](CO)O3)O)[C@H](O)[C@H](CO)O2)NC(C)=O)[C@H](CO)O1 NVNPEYQWKCQBBU-ADMXJUBYSA-N 0.000 description 6
- 235000004035 Cryptotaenia japonica Nutrition 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 108010021466 Mutant Proteins Proteins 0.000 description 6
- 102000008300 Mutant Proteins Human genes 0.000 description 6
- 102000007641 Trefoil Factors Human genes 0.000 description 6
- 235000015724 Trifolium pratense Nutrition 0.000 description 6
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 238000010186 staining Methods 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 5
- 241000282898 Sus scrofa Species 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 5
- 210000004899 c-terminal region Anatomy 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000005847 immunogenicity Effects 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 241000283707 Capra Species 0.000 description 4
- 108091026890 Coding region Proteins 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 108091006054 His-tagged proteins Proteins 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 238000001042 affinity chromatography Methods 0.000 description 4
- 230000003302 anti-idiotype Effects 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- -1 for example Chemical class 0.000 description 4
- 230000002990 hypoglossal effect Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 210000004962 mammalian cell Anatomy 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 238000002703 mutagenesis Methods 0.000 description 4
- 231100000350 mutagenesis Toxicity 0.000 description 4
- 239000002581 neurotoxin Substances 0.000 description 4
- 231100000618 neurotoxin Toxicity 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 230000000717 retained effect Effects 0.000 description 4
- 150000003839 salts Chemical group 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 229920000936 Agarose Polymers 0.000 description 3
- 241001112695 Clostridiales Species 0.000 description 3
- 238000001712 DNA sequencing Methods 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 108010025020 Nerve Growth Factor Proteins 0.000 description 3
- 102000015336 Nerve Growth Factor Human genes 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 229930040373 Paraformaldehyde Natural products 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 206010043376 Tetanus Diseases 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 238000007413 biotinylation Methods 0.000 description 3
- 230000006287 biotinylation Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 230000009089 cytolysis Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 239000003008 fumonisin Substances 0.000 description 3
- 210000004408 hybridoma Anatomy 0.000 description 3
- 238000005304 joining Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229940053128 nerve growth factor Drugs 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 229920002866 paraformaldehyde Polymers 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 229920002704 polyhistidine Polymers 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 238000000159 protein binding assay Methods 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 230000009844 retrograde axon cargo transport Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 210000002504 synaptic vesicle Anatomy 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000588832 Bordetella pertussis Species 0.000 description 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- 241000672609 Escherichia coli BL21 Species 0.000 description 2
- 229920003134 Eudragit® polymer Polymers 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102000005720 Glutathione transferase Human genes 0.000 description 2
- 108010070675 Glutathione transferase Proteins 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 108090000526 Papain Proteins 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 241000714474 Rous sarcoma virus Species 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 241000607149 Salmonella sp. Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical group C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- NWMHDZMRVUOQGL-CZEIJOLGSA-N almurtide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)CO[C@@H]([C@H](O)[C@H](O)CO)[C@@H](NC(C)=O)C=O NWMHDZMRVUOQGL-CZEIJOLGSA-N 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 238000001949 anaesthesia Methods 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- KQHXBDOEECKORE-UHFFFAOYSA-L beryllium sulfate Chemical compound [Be+2].[O-]S([O-])(=O)=O KQHXBDOEECKORE-UHFFFAOYSA-L 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000000133 brain stem Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 229940055729 papain Drugs 0.000 description 2
- 235000019834 papain Nutrition 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 230000006337 proteolytic cleavage Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- MIJDSYMOBYNHOT-UHFFFAOYSA-N 2-(ethylamino)ethanol Chemical compound CCNCCO MIJDSYMOBYNHOT-UHFFFAOYSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 1
- 208000020154 Acnes Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 239000012583 B-27 Supplement Substances 0.000 description 1
- 238000000035 BCA protein assay Methods 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 101100404144 Bacillus subtilis (strain 168) nasD gene Proteins 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 101100327537 Caenorhabditis elegans cgp-1 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000589994 Campylobacter sp. Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 108010039939 Cell Wall Skeleton Proteins 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 241000193163 Clostridioides difficile Species 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241001131785 Escherichia coli HB101 Species 0.000 description 1
- IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical compound OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 108050001049 Extracellular proteins Proteins 0.000 description 1
- 102100039556 Galectin-4 Human genes 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000608765 Homo sapiens Galectin-4 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 229930195714 L-glutamate Natural products 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
- 239000006137 Luria-Bertani broth Substances 0.000 description 1
- 229920002858 MOWIOL ® 4-88 Polymers 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- BAQCROVBDNBEEB-UBYUBLNFSA-N Metrizamide Chemical compound CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C(=O)N[C@@H]2[C@H]([C@H](O)[C@@H](CO)OC2O)O)=C1I BAQCROVBDNBEEB-UBYUBLNFSA-N 0.000 description 1
- 241000713869 Moloney murine leukemia virus Species 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 108700015872 N-acetyl-nor-muramyl-L-alanyl-D-isoglutamine Proteins 0.000 description 1
- 108700020354 N-acetylmuramyl-threonyl-isoglutamine Proteins 0.000 description 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 101710138657 Neurotoxin Proteins 0.000 description 1
- 229910021586 Nickel(II) chloride Inorganic materials 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010002747 Pfu DNA polymerase Proteins 0.000 description 1
- 241000223960 Plasmodium falciparum Species 0.000 description 1
- 108010039918 Polylysine Chemical group 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 101000993333 Rattus norvegicus Ciliary neurotrophic factor Proteins 0.000 description 1
- 101000997827 Rattus norvegicus Glial cell line-derived neurotrophic factor Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 102000000159 Synaptotagmin II Human genes 0.000 description 1
- 108010055445 Synaptotagmin II Proteins 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000003217 Tetany Diseases 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical group OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 102000003786 Vesicle-associated membrane protein 2 Human genes 0.000 description 1
- 108090000169 Vesicle-associated membrane protein 2 Proteins 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229940103272 aluminum potassium sulfate Drugs 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- RIIWUGSYXOBDMC-UHFFFAOYSA-N benzene-1,2-diamine;hydron;dichloride Chemical compound Cl.Cl.NC1=CC=CC=C1N RIIWUGSYXOBDMC-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000004520 cell wall skeleton Anatomy 0.000 description 1
- 210000004671 cell-free system Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 101150018266 degP gene Proteins 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000011990 functional testing Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 101150007310 htrA gene Proteins 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 210000001926 inhibitory interneuron Anatomy 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- UOEFDXYUEPHESS-QMGXLNLGSA-N isopropyl beta-D-galactopyranoside Chemical compound CC(C)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O UOEFDXYUEPHESS-QMGXLNLGSA-N 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- VCMGMSHEPQENPE-UHFFFAOYSA-N ketamine hydrochloride Chemical compound [Cl-].C=1C=CC=C(Cl)C=1C1([NH2+]C)CCCCC1=O VCMGMSHEPQENPE-UHFFFAOYSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 230000000503 lectinlike effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 229960001614 levamisole Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- HEHQDWUWJVPREQ-XQJZMFRCSA-N lipid X Chemical compound CCCCCCCCCCC[C@@H](O)CC(=O)N[C@H]1[C@@H](OP(O)(O)=O)O[C@H](CO)[C@@H](O)[C@@H]1OC(=O)C[C@H](O)CCCCCCCCCCC HEHQDWUWJVPREQ-XQJZMFRCSA-N 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 238000007898 magnetic cell sorting Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
- 229960000554 metrizamide Drugs 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- JMUHBNWAORSSBD-WKYWBUFDSA-N mifamurtide Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)COP(O)(=O)OCCNC(=O)[C@H](C)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1NC(C)=O JMUHBNWAORSSBD-WKYWBUFDSA-N 0.000 description 1
- 229960005225 mifamurtide Drugs 0.000 description 1
- 108700007621 mifamurtide Proteins 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 230000003957 neurotransmitter release Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- QMMRZOWCJAIUJA-UHFFFAOYSA-L nickel dichloride Chemical compound Cl[Ni]Cl QMMRZOWCJAIUJA-UHFFFAOYSA-L 0.000 description 1
- 101150044129 nirB gene Proteins 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- 101150093139 ompT gene Proteins 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 210000002856 peripheral neuron Anatomy 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920000656 polylysine Chemical group 0.000 description 1
- 108010055896 polyornithine Proteins 0.000 description 1
- 229920002714 polyornithine Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- GRLPQNLYRHEGIJ-UHFFFAOYSA-J potassium aluminium sulfate Chemical compound [Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O GRLPQNLYRHEGIJ-UHFFFAOYSA-J 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000003518 presynaptic effect Effects 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 230000018883 protein targeting Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 229940124551 recombinant vaccine Drugs 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 210000001995 reticulocyte Anatomy 0.000 description 1
- 229940069575 rompun Drugs 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 125000005629 sialic acid group Chemical group 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 210000003594 spinal ganglia Anatomy 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000003363 transsynaptic effect Effects 0.000 description 1
- XETCRXVKJHBPMK-MJSODCSWSA-N trehalose 6,6'-dimycolate Chemical compound C([C@@H]1[C@H]([C@H](O)[C@@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](COC(=O)C(CCCCCCCCCCC3C(C3)CCCCCCCCCCCCCCCCCC)C(O)CCCCCCCCCCCCCCCCCCCCCCCCC)O2)O)O1)O)OC(=O)C(C(O)CCCCCCCCCCCCCCCCCCCCCCCCC)CCCCCCCCCCC1CC1CCCCCCCCCCCCCCCCCC XETCRXVKJHBPMK-MJSODCSWSA-N 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- QYEFBJRXKKSABU-UHFFFAOYSA-N xylazine hydrochloride Chemical compound Cl.CC1=CC=CC(C)=C1NC1=NCCCS1 QYEFBJRXKKSABU-UHFFFAOYSA-N 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Definitions
- This invention relates to polypeptides derived from fragment C of the tetanus toxin and their use in vaccine compositions.
- Tetanus is a highly infectious, worldwide disease caused by the organism Clostridium tetani. Its spores can remain dormant for indefinite periods in house dust and soil which are the prime sources of infection for open wounds. Contaminated animal faeces are also responsible for the spread of the disease and may further contaminate previously uninfected locales.
- Tetanus infection is always a risk for the wounded and is usually associated with great pain and may even lead to death.
- causative agent was discovered to be a bacterium, great effort was devoted to the development of an effective vaccine.
- the first successful vaccination in human subjects was carried out in 1926, when the vaccine used comprised crude tetanus toxin treated to render it atoxic.
- Tetanus toxin provided the target for the first vaccine as it had already been discovered that symptoms are not due to the bacterium infecting host cells but rather by a potent neurotoxin released upon lysis of the bacterial cells.
- a single (parent) peptide is synthesised which comprises both light and heavy chains.
- an endogenous protein cleaves the peptide between a preexisting disulphide bridge to give two peptide chains linked by a disulphide bridge.
- Papain cleaves the heavy chain to give a fragment B (100 kDa) consisting of the light chain and part of the heavy chain, and a fragment C (50 kDa). consisting of the remainder of the heavy chain. It has been shown that both fragments are capable of providing protection but may be associated with residual toxicity that would be due to contamination with uncleaved toxin.
- Tetanus toxin is a member of the family of clostridial neurotoxins (CNTs) which includes the botulinum toxins (BoNTs). CNTs inhibit neurotransmitter release from presynaptic neuronal cells by proteolytic cleavage of proteins involved in the fusion of synaptic vesicles with the cell membrane. This cleavage is catalysed by the 50 kDa L-chain of CNTs which encodes a zinc dependent metaloprotease. The overall structural and functional properties of the CNTs are very similar, having a similar sub-unit structure and 30-40% amino acid identity (Minton, 1995).
- TeNT In contrast to BoNTs which remain within the peripheral nervous system, TeNT is trafficked to the central nervous system by retrograde axonal transport followed by trans-synaptic spread into inhibitory interneurons. It is this differential cellular trafficking of TeNT compared to the BoNTs which explains the distinct sites of action of the toxins and therefore the distinct clinical symptoms of the two diseases.
- TeNT and BoNT bind to sensitive cells in a variety of in vitro systems including tissue preparations, primary cell cultures and cell lines. These studies, and others, have shown that TeNT and BoNT bind to membrane receptors, and are internalised prior to the cytosolic action of the L-chain of the toxins. The steps involved in binding and trafficking of TeNT are largely uncharacterised, although it appears to involve internalisation through uptake of small synaptic vesicles during vesicle reuptake. The binding of TeNT to neuronal tissue involves the C-terminal 50 kDa domain (He domain, also known as fragment C).
- TeNT He fragment blocked uptake of TeNT as shown by inhibition of VAMP-2 cleavage and antagonism of neuromuscular transmission, indicating that the binding of He is functional.
- the He fragment alone retains the ability to undergo retrograde transport in vivo, and has been used as a carrier of foreign proteins to the CNS. Since the initial demonstration of TeNT binding to gangliosides, many studies have attempted to characterise binding of CNTs to gangliosides using in vitro and in vivo assays.
- synaptotagmin II which is localised in the lumen of small synaptic vesicles, has been identified as a protein receptor for BoNT serotype B, and serotypes A and E.
- Cross-linking experiments using primary spinal cord motoneurons and NGF-differentiated PC 12 cells have identified a 15 kDa glycoprotein as a possible neuronal receptor for TeNT (Herreros, et al. J. Neurochemsitry in press). This receptor binds only to the carboxy terminal half of the He domain of TeNT.
- Mutant molecules were produced in E.coli, purified and assayed in ganglioside binding, cell binding and in vivo retrograde transport assays. Our results identify specific residues that are required for ganglioside binding, and identify certain mutants with reduced ganglioside binding but which still retain the ability to bind primary neuronal cells and undergo retrograde axonal transport.
- the TeNT fragment C required for binding gangliosides deletion of which leads to a greater reduction in ganglioside binding than the results obtained for His 1293 alone.
- the regions are loop regions which connect two sections of ⁇ sheet.
- the present invention provides a polypeptide comprising tetanus toxin (TeNT) fragment C, or an immunogenic fragment thereof, which tetanus toxin fragment C, or immunogenic fragment thereof comprises a mutation in a loop region, which mutation results in a reduction in the binding of the tetanus toxin fragment C, or immunogenic fragment thereof, to gangliosides.
- TeNT tetanus toxin
- the present invention also provides a polypeptide comprising tetanus toxin (TeNT) fragment C, or an immunogenic fragment thereof, which tetanus toxin fragment C. or immunogenic fragment thereof comprises a mutation in a loop region, which mutation results in a reduction in the binding of the tetanus toxin fragment C, or immunogenic fragment thereof, to primary motoneurones.
- TeNT tetanus toxin
- the present invention also provides a polypeptide comprising tetanus toxin (TeNT) fragment C, or an immunogenic fragment thereof, which tetanus toxin fragment C. or immunogenic fragment thereof comprises a mutation in a loop region, which mutation results in a reduction in the ability of the tetanus toxin fragment C, or immunogenic fragment thereof, to undergo retrograde transport.
- TeNT tetanus toxin
- the mutation results in a reduction in the binding of the tetanus toxin fragment C (or immunogenic fragment thereof) to gangliosides and a reduction in the binding to primary motoneurones and/or a reduction in the ability to undergo retrograde transport.
- said loop region is present in the full length wild type sequence between two ⁇ sheets. More preferably said loop region is selected from amino acid residues 1214 to 1219 and 1271 to 1282 of the amino acid sequence of TeNT fragment C.
- said mutation is at least one deletion, more preferably at least one deletion selected from ⁇ 1214 to 1219, ⁇ 1274 to 1279 and ⁇ 1271 to 1282 of the amino acid sequence of TeNT fragment C.
- the present invention further provides a polynucleotide encoding a polypeptide of the invention.
- the present invention also provides vectors comprising a polynucleotide encoding a polypeptide of the invention operably linked to a regulatory sequence.
- a regulatory sequence allows expression of the polypeptide in a host cell.
- the host cell is a bacterium, or a cell of an animal, more preferably a mammal, including primates and humans.
- polypeptides, polynucleotides and vectors of the present invention may be used in the prevention (or reduction in susceptibility to), or treatment of, Clostridium tetani infections.
- the present invention provides a pharmaceutical composition comprising a polypeptide, polynucleotide or vector of the invention together with a pharmaceutically acceptable carrier or diluent.
- the present invention also provides a method of treating or preventing C. tetani infection in a human or animal which comprises administering to the human or animal an effective amount of a polypeptide, polynucleotide or vector of the invention.
- the present invention further provides a polypeptide of the present invention for use in therapy, such as the prevention (or reduction in susceptibility to), or treatment of, C. tetani infections. Also provided is the use of a polypeptide of the invention in the manufacture of a medicament for use in the prevention (or reduction in susceptibility to), or treatment of. C. tetani infections.
- the invention provides the use of a polypeptide. polynucleotide or vector of the invention in a method for producing antibodies which recognise epitopes within a TeNT polypeptide.
- the present invention provides a method for producing antibodies which recognise epitopes within a TeNT polypeptide which method comprises administering a polypeptide, a polynucleotide or a vector of the invention to a mammal.
- Such antibodies produced by the various methods known in the art may be used in a method of treating C. tetani infection in a human or animal which comprises administering to a human or animal an effective amount of an antibody produced by the above method of the invention.
- the invention provides a method for reducing the binding affinity of a TeNT fragment C polypeptide for gangliosides which method comprises modifying one or more amino acid residues present in a surface-exposed loop region of the polypeptide. Also provided is a polypeptide produced by said method.
- fragment C is a 50 kDa polypeptide generated by papain cleavage and comprises or substantially corresponds to the 451 amino acids at the C-terminus.
- fragment C and “He” are used interchangeably herein. It is to be understood that although the description below adopts the amino acid numbering based on the sequence of tetanus toxin described herein, the present invention is equally applicable to fragment C variants found in other strains of C. tetani (which may have slightly different amino acid numbering).
- Polvpeptides of the invention comprise tetanus toxin fragment C or immunogenic g fragments thereof that have been modified to reduce their ability to bind to gangliosides, and/or their ability to bind primary motoneurones, and/or their ability to undergo retrograde transport.
- the polypeptides of the invention comprise mutations in a loop region found between 2 ⁇ sheets.
- the 3D structure of TeNT fragment C has been determined by Umland et al. (1997) the structural coordinates deposited in the Protein Data Bank under reference number laf9.
- the structural information presented in Umland et al. (1997) (see Figure la in particular) allows the skilled person to identify candidate loop regions. Preferably these loops are exposed on the surface of the molecule.
- the first loop consists of approximately amino acids 1214 to 1219 and the second loop consists of approximately amino acids 1271 to 1282.
- Mutations in the loop regions may be substitutions, insertions and/or deletions.
- the mutations are deletions, more preferably deletions which remove substantially all of a particular loop region.
- Techniques for modifying amino acids sequences are well known in the art, such as PCR-directed mutagenesis.
- mutant TeNT polypeptides of the present invention have less than 50% ganglioside binding activity compared with wild type TeNT, more preferably less than 40. 30. 20 or 10%), most preferably less than 5%.
- Ganglioside binding activity may. for example, be determined in vitro as described in the examples.
- mutant TeNT polypeptides of the present invention have less than 50% neuronal cell binding activity compared with wild type TeNT, more preferably less than 40. 30, 20 or 10%. most preferably less than 5%.
- Neuronal cell binding activity may, for example, be determined as described in the examples.
- mutant polypeptides of the invention retain at least 50% of the immunogenicity of the wild type sequence from which they are derived (i.e. the full WO 01/00839 .9. PCT/GBOO/02428 length fragment C sequence or immunogenic fragments thereof), more preferably at least 70, 80 or 90%.
- Immunogenicity may be determined typically by the use of in vitro techniques such as ELISA or Western blotting.
- immunogenicity may be determined in vivo by, for example, immunising animals with a polypeptide of the invention and then either testing sera by ELISA or Western blotting, or by subsequently challenging immunised individuals with active toxin.
- a polypeptide of the invention comprises TeNT fragment C, or an immunogenic fragment thereof, which TeNT fragment C, or immunogenic fragment thereof, comprise a mutation in amino acid residues 1214 to 1219 and/or 1271 to 1282.
- a polypeptide of the invention comprises TeNT fragment C, or an immunogenic fragment thereof, which TeNT fragment C. or immunogenic fragment thereof, comprises a deletion of amino acid residues 1214 to 1219 and/or at least 1274 to 1279, more preferably 1271 to 1282.
- polypeptides of the invention further comprise a modification at residue His-1293, preferably a substitution such as His ⁇ Ala or His- ⁇ Ser.
- Fragments of tetanus toxin fragment C that contain epitopes may also be used in the poK ⁇ eptides of the invention. These fragments will comprise at least 5 or 6 amino acids, preferably at least 10 amino acids, more preferably at least 15. 20. 50 or 100 amino acids. Particularly preferred fragments include from about amino acids 943 to 1023. which is a good B-cell epitope, and from about amino acids 946 to 966 which is a good T-cell epitope. All amino acid numbering is with reference to the full-length toxin gene.
- amino acid sequence of tetanus toxin fragment C can be further modified to provide polypeptides of the invention. For example, this may be carried out to enhance the immunogenicity of the polypeptides of the invention. Amino acid substitutions may be made, for example from 1, 2 or 3 to 10. 20 or 30 substitutions provided that the modified polypeptide retains epitopes.
- Polypeptides of the invention may further comprise heterologous amino acid sequences, typically at the N-terminus or C-terminus, preferably the N-terminus.
- Heterologous sequences may include sequences that affect intra or extracellular protein targeting (such as leader sequences).
- Heterologous sequences may also include sequences that increase the immunogenicity of the polypeptide of the invention and/or which facilitate identification, extraction and/or purification of the polypeptides.
- Another heterologous sequence that is particularly preferred is a polyamino acid sequence such as polyhistidine which is preferably N-terminal.
- a polyhistidine sequence of at least 10 amino acids, preferably at least 17 amino acids but fewer than 50 amino acids is especially preferred.
- heterologous amino acid sequences includes immunogenic sequences from other pathogenic organisms such as bacteria or viruses. Examples include pathogenic E. coli, Neiserria sp., B. pertussis, C. difficile, Salmonella sp., Campylobacter sp., P. falciparum, hepatitis B virus, hepatitis C virus and human papilloma virus. Conveniently, these immunogenic sequences may be inserted into a loop region which it is desired to disrupt (such as amino acids 1214 to 1219).
- Polypeptides of the invention are typically made by recombinant means, for example as described below. However they may also be made by synthetic means using techniques well known to skilled persons such as solid phase synthesis. Polypeptides of the invention may also be produced as fusion proteins, for example to aid in extraction and purification. Examples of fusion protein partners include glutathione-S-transferase (GST), 6xHis, GAL4 (DNA binding and/or transcriptional activation domains) and ⁇ -galactosidase. It may also be convenient to include a proteolytic cleavage site between the fusion protein partner and the protein sequence of interest to allow removal of fusion protein sequences, such as a thrombin cleavage site. Preferably the fusion protein will not hinder the function of the protein of interest sequence.
- Polypeptides of the invention may be in a substantially isolated form. It will be understood that the protein may be mixed with carriers or diluents which will not interfere with the intended purpose of the protein and still be regarded as substantially isolated.
- a polypeptide of the invention may also be in a substantially purified form, in which case it will generally comprise the protein in a preparation in which more than 90%o, e.g. 95%. 98% or 99%o of the protein in the preparation is a polypeptide of the invention.
- Polynucleotides of the invention comprise nucleic acid sequences encoding the polypeptides of the invention.
- Polynucleotides of the invention may comprise DNA or RNA. They may also be polynucleotides which include within them synthetic or modified nucleotides. A number of different types of modification to oligonucleotides are known in the art. These include methylphosphonate and phosphorothioate backbones, addition of acridine or polylysine chains at the 3' and/or 5' ends of the molecule.
- the polynucleotides described herein may be modified by any method available in the art. Such modifications may be carried out in order to enhance the in vivo activity or life span of polynucleotides of the invention.
- Preferred polynucleotides of the invention also include polynucleotides encoding any of the polypeptides of the invention described above. It will be understood by a skilled person that numerous different polynucleotides can encode the same polypeptide as a result of the degeneracy of the genetic code.
- Polynucleotides of the invention can be incorporated into a recombinant replicable vector.
- the vector may be used to replicate the nucleic acid in a compatible host cell.
- the invention provides a method of making polynucleotides of the invention by introducing a polynucleotide of the invention into a replicable vector, introducing the vector into a compatible host cell, and growing the host cell under conditions which bring about replication of the vector.
- the vector may be recovered from the host cell.
- Suitable host cells include bacteria such as E. coli, yeast, mammalian cell lines and other eukaryotic cell lines, for example insect Sf9 cells.
- a polynucleotide of the invention in a vector is operably linked to a regulator ⁇ ' sequence that is capable of providing for the expression of the coding sequence by the host cell, i.e. the vector is an expression vector.
- the term "operably linked'" refers to a juxtaposition wherein the components described are in a relationship permitting them to function in their intended manner.
- a regulatory sequence "operably linked" to a coding sequence is ligated in such a way that expression of the coding sequence is achieved under conditions compatible with the control sequences.
- Such vectors ma)' be transformed or transfected into a suitable host cell as described above to provide for expression of a polypeptide of the invention.
- This process may comprise culturing a host cell transformed with an expression vector as described above under conditions to provide for expression by the vector of a coding sequence encoding the polypeptides. and optionally recovering the expressed polypeptides.
- the vectors may be, for example, plasmid or virus vectors provided with an origin of replication, optionally a promoter for the expression of the said polynucleotide and optionally a regulator of the promoter.
- the vectors may contain one or more selectable marker genes, for example an ampicillin resistance gene in the case of a bacterial plasmid or a neomycin resistance gene for a mammalian vector.
- Vectors may be used in vitro, for example for the production of RNA or used to transfect or transform a host cell.
- the vector may also be adapted to be used in vivo, for example in a method of gene therapy.
- Promoters/enhancers and other expression regulation signals may be selected to be compatible with the host cell for which the expression vector is designed.
- prokaryotic promoters may be used, in particular those suitable for use in E. coli strains (such as E. coli HB101).
- an htrA or nirB promoter may be used.
- mammalian promoters may be used.
- Tissue-specific promoters may also be used.
- Viral promoters may also be used, for example the Moloney murine leukaemia virus long terminal repeat (MMLV LTR), the promoter rous sarcoma virus (RSV) LTR promoter, the SV40 promoter, the human cytomegalovirus (CMV) IE promoter, herpes simplex virus promoters or adenovirus promoters. All these promoters are readily available in the art.
- MMLV LTR Moloney murine leukaemia virus long terminal repeat
- RSV promoter rous sarcoma virus
- CMV human cytomegalovirus
- IE herpes simplex virus promoters or adenovirus promoters. All these promoters are readily available in the art.
- Vectors and polynucleotides of the invention may be introduced into host cells for the purpose of replicating the vectors/polynucleotides and/or expressing the polypeptides of the invention encoded by the polynucleotides of the invention.
- Suitable host cells include prokaryotes such as eubacteria, for example E. coli and B. subtilis and eukaryotes such as yeast, insect or mammalian cells.
- Vectors/polynucleotides of the invention may be introduced into suitable host cells using a variety of techniques known in the art, such as transfection, transformation and electroporation. Where vectors/polynucleotides of the invention are to be administered to animals, several techniques are known in the art, for example infection with recombinant viral vectors such as retroviruses, herpes simplex viruses and adenoviruses. direct injection of nucleic acids and biolistic transformation.
- Host cells comprising polynucleotides of the invention may be used to express polypeptides of the invention.
- Host cells may be cultured under suitable conditions which allow expression of the proteins of the invention.
- Expression of the polypeptides of the invention may be constitutive such that they are continually produced, or inducible, requiring a stimulus to initiate expression. In the case of inducible expression, protein production can be initiated when required by. for example, addition of an inducer , A
- -14- substance to the culture medium, for example dexamethasone or IPTG.
- Suitable methods for producing tetanus toxin fragment C polypeptides are described in WO-A-9015871 and
- Polypeptides of the invention can be extracted from host cells by a variety of techniques known in the art, including enzymatic, chemical and/or osmotic lysis and physical disruption.
- polypeptides may optionally be performed using well known techniques such as affinity chromatography. including immuno affinity chromatography, ion-exchange chromatography and the like.
- affinity chromatography including immuno affinity chromatography, ion-exchange chromatography and the like.
- a particularly preferred technique is to express the polypeptide of the invention as a fusion protein with polyhistidine tag (for example 6xHis) and purify cell extracts using Ni-NTA agarose (Qiagen).
- polyhistidine tag for example 6xHis
- Qiagen Ni-NTA agarose
- Polypeptides of the invention may also be produced recombinantly in an in vitro cell-free system, such as the TnTTM (Promega) rabbit reticulocyte system.
- the polypeptides of the invention may be administered by direct injection.
- the polypeptides are combined with a pharmaceutically acceptable carrier or diluent to produce a pharmaceutical composition, which may be for human or veterinary use.
- Suitable carriers and diluents include isotonic saline solutions, for example phosphate-buffered saline.
- the composition may be formulated for parenteral, intramuscular, intravenous, subcutaneous, intraocular or transdermal administration.
- each polypeptide is administered at a dose of from 0.01 to 30 ⁇ g/kg body weight, preferably from 0.1 to 10 ⁇ g/kg. more preferably from 0.1 to 1 ⁇ g/kg body weight.
- antibodies prepared using the polypeptides of the invention can be administered in a similar manner to the polypeptides of the invention.
- the polynucleotides of the invention may be administered directly as a naked nucleic acid construct, preferably further comprising flanking sequences homologous to the host cell genome.
- the amount of nucleic acid administered is typically in the range of from 1 ⁇ g to 10 mg, preferably from 100 ⁇ g to 1 mg.
- Uptake of naked nucleic acid constructs by mammalian cells is enhanced by several known transfection techniques for example those including the use of transfection agents.
- transfection agents include cationic agents (for example calcium phosphate and DEAE-dextran) and lipofectants (for example lipofectamTM and transfectamTM).
- cationic agents for example calcium phosphate and DEAE-dextran
- lipofectants for example lipofectamTM and transfectamTM.
- nucleic acid constructs are mixed with the transfection agent to produce a composition.
- a nucleotide of the invention is introduced into an attenuated strain of Salmonella sp. such that a polypeptide of the invention is expressed by the transformed bacterial strain and the live bacteria administered, typically orally, to a patient.
- the polynucleotide or vector of the invention is combined with a pharmaceutically acceptable carrier or diluent to produce a pharmaceutical composition.
- Suitable carriers and diluents include isotonic saline solutions, for example phosphate- buffered saline.
- the composition may be formulated for parenteral. intramuscular, intravenous, subcutaneous, intraocular or transdermal administration.
- Vaccines may be prepared from one or more polypeptides of the invention.
- the preparation of vaccines which contain an immunogenic polypeptide(s) as active ingredient(s), is known to one skilled in the art.
- such vaccines are prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid prior to injection may also be prepared.
- the preparation may also be emulsified, or the protein encapsulated in liposomes.
- the active immunogenic ingredients are often mixed with excipients which are pharmaceutically acceptable and compatible with the active ingredient. Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol, or the like and combinations thereof.
- the vaccine may contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents, and/or adjuvants which enhance the effectiveness of the vaccine.
- auxiliary substances such as wetting or emulsifying agents, pH buffering agents, and/or adjuvants which enhance the effectiveness of the vaccine.
- adjuvants which may be effective include but are not limited to: aluminum hydroxide, N-acetyl-muramyl-L-tlrreonyl-D-isoglutamine (thr-MDP), N-acetyl-nor-muramyl-L-alanyl-D-isoglutamine (CGP 1 1637.
- nor-MDP N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(T-2'-dipalmitoyl-sn- glycero-3-hydroxyphosphoryloxy)-ethylamine
- CGP 19835 A referred to as MTP-PE
- RIBI N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(T-2'-dipalmitoyl-sn- glycero-3-hydroxyphosphoryloxy)-ethylamine
- MTP-PE N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(T-2'-dipalmitoyl-sn- glycero-3-hydroxyphosphoryloxy)-ethylamine
- MTP-PE N-acetylmuramyl-L-alanyl-
- adjuvants and other agents include aluminum hydroxide, aluminum phosphate, aluminum potassium sulfate (alum), beryllium sulfate, silica, kaolin, carbon, water-in-oil emulsions, oil-in-water emulsions, muramyl dipeptide, bacterial endotoxin, lipid X, Corynebacterium parvum (Propionobacterium acnes), Bordetella pertussis, polyribonucleotides. sodium alginate, lanolin, lysolecithin, vitamin A, saponin, liposomes. levamisole, DEAE-dextran, blocked copolymers or other synthetic adjuvants.
- Such adjuvants are available commercially from various sources, for example, Merck Adjuvant 65 (Merck and Company, Inc.. Rahway, N.J.) or Freund's Incomplete Adjuvant and Complete Adjuvant (Difco Laboratories, Detroit, Michigan).
- adjuvants such as Amphigen (oil-in-water).
- Alhydrogel aluminum hydroxide
- Amphigen oil-in-water
- Alhydrogel aluminum hydroxide
- the proportion of immunogen and adjuvant can be varied over a broad range so long as both are present in effective amounts.
- aluminum hydroxide can be present in an amount of about 0.5% of the vaccine mixture (Al O 3 basis).
- the vaccines are formulated to contain a final concentration of immunogen in the range of from 0.2 to 200 ⁇ g/ml, preferably 5 to 50 ⁇ g/ml, most preferably 15 ⁇ g/ml.
- the vaccine may be incorporated into a sterile container which is then sealed and stored at a low temperature, for example 4°C. or it may be freeze-dried. Lyophilisation permits long-term storage in a stabilised form.
- the effectiveness of an adjuvant may be determined by measuring the amount of antibodies directed against an immunogenic polypeptide containing a TeNT antigenic sequence resulting from administration of this polypeptide in vaccines which are also comprised of the various adjuvants.
- the vaccines are conventionally administered parenterally, by injection, for example, either subcutaneously or intramuscularly.
- Additional formulations which are suitable for other modes of administration include suppositories and. in some cases, oral formulations.
- suppositories traditional binders and carriers may include, for example, polyalkylene glycols or triglycerides; such suppositories may be formed from mixtures containing the active ingredient in the range of 0.5% to 10%. preferably 1% to 2%.
- Oral formulations include such normally employed excipients as. for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate. sodium saccharine, cellulose, magnesium carbonate, and the like.
- compositions take the form of solutions, suspensions, tablets, pills, capsules, sustained release formulations or powders and contain 10% to 95% of active ingredient, preferably 25% to 70%.
- the vaccine composition is lyophilised.
- the lyophilised material may be reconstituted prior to administration, e.g. as a suspension. Reconstitution is preferably effected in buffer
- Capsules, tablets and pills for oral administration to a patient may be provided with an enteric coating comprising, for example, Eudragit "S”, Eudragit "L”, cellulose acetate, cellulose acetate phthalate or hydroxypropylmethyl cellulose.
- the polypeptides of the invention may be formulated into the vaccine as neutral or salt forms.
- Pharmaceutically acceptable salts include the acid addition salts (formed with free amino groups of the peptide) and which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids such as acetic, oxalic, tartaric and maleic. Salts formed with the free carboxyl groups may also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine. 2-ethylamino ethanol. histidine and procaine.
- the vaccines are administered in a manner compatible with the dosage formulation, and in such amount as will be prophylactically and/or therapeutically effective.
- the quantity to be administered which is generally in the range of 5 ⁇ g to 250 ⁇ g of antigen per dose, depends on the subject to be treated, capacity of the subject's immune system to synthesize antibodies, and the degree of protection desired. A preferable range is from about 20 ⁇ g to about 40 ⁇ g per dose.
- a suitable dose size is about 0.5 ml. Accordingly, a dose for intramuscular injection, for example, would comprise 0.5 ml containing 20 ⁇ g of immunogen in admixture with 0.5%o aluminum hydroxide.
- Precise amounts of active ingredient required to be administered may depend on the judgement of the practitioner and may be peculiar to each subject.
- the vaccine may be given in a single dose schedule, or preferably in a multiple dose schedule.
- a multiple dose schedule is one in which a primary course of vaccination may be with 1-10 separate doses, followed by other doses given at subsequent time intervals required to maintain and or reinforce the immune response, for example, at 1 to 4 months for a second dose, and if needed, a subsequent dose(s) after several months.
- the dosage regimen will also, at least in part, be determined by the need of the individual and be dependent upon the judgement of the practitioner.
- the vaccine containing the immunogenic TeNT antigen(s) may be administered in conjunction with other immunoregulatory agents, for example, immunoglobulins.
- the immunogenic polypeptides prepared as described above can be used to produce antibodies, both polyclonal and monoclonal. If polyclonal antibodies are desired, a selected mammal (e.g.. mouse, rabbit, goat, horse, etc.) is immunised with an immunogenic polypeptide bearing a TeNT epitope(s). Serum from the immunised animal is collected and treated according to known procedures. If serum containing polyclonal antibodies to a TeNT epitope contains antibodies to other antigens, the polyclonal antibodies can be purified by immunoaffinity chromatography. Techniques for producing and processing polyclonal antisera are known in the art.
- Monoclonal antibodies directed against TeNT epitopes in the polypeptides of the invention can also be readily produced by one skilled in the art.
- the general methodology for making monoclonal antibodies by hybridomas is well known.
- Immortal antibody- producing cell lines can be created by cell fusion, and also by other techniques such as direct transformation of B lymphocytes with oncogenic DNA, or transfection with Epstein- Barr virus.
- Panels of monoclonal antibodies produced against TeNT epitopes can be screened for various properties; i.e., for isotype and epitope affinity.
- An alternative technique involves screening phage display libraries where, for example the phage express scFv fragments on the surface of their coat with a large variety of complementarity determining regions (CDRs). This technique is well known in the art.
- Antibodies both monoclonal and polyclonal, which are directed against TeNT epitopes are particularly useful in diagnosis, and those which are neutralising are useful in passive immunotherapy.
- Monoclonal antibodies in particular, may be used to raise anti-idiotype antibodies.
- Anti-idiotype antibodies are immunoglobulins which carry an "internal image" of the antigen of the infectious agent against which protection is desired.
- anti-idiotype antibodies may also be useful for treatment of C. tetani, as well as for an elucidation of the immunogenic regions of C. tetani antigens.
- the term "antibody”, unless specified to the contrary, includes fragments of whole antibodies which retain their binding activity for a target antigen. Such fragments include Fv, F(ab') and F(ab') 2 fragments, as well as single chain antibodies (scFv). Furthermore, the antibodies and fragments thereof may be humanised antibodies, for example as described in EP-A-239400.
- Figure 1 is a 3D representation of the structure of tetanus toxin fragment C.
- Figure 2 is a graph showing % binding to gangliosides compared with wild type for various TeNT fragment C mutants.
- E. coli strain BL21 ( ⁇ DE3, ompT, hsdS H (r B -m B -), gal, dcm) was used as the host for the plasmids described below.
- Plasmid pKSl contains a codon-optimised gene for the expression of the He fragment of TeNT under the control of the T7 promoter.
- the Ndel - BamHl fragment was purified by agarose gel electrophoresis using a Qiaex II gel purification kit (Qiagen, West Wales, UK), and sublconed into pET28a (Novagen, Cambridge UK) which had previously been digested with Ndel and BamHl (Roche Molecular Biochemicals, East Wales, UK). DNA manipulations were performed by standard procedures.
- Mutagenesis was performed using the QuikChangeTM site-directed mutagenesis kit (Stratagene). Pairs of complementary oligonucleotides were used to construct mutant He molecules (see Table 1). To create mutants containing single amino acid mutations (Ml 5, M24. M667, M564 and M57), the following cycles were used with pKSl as template DNA: Step 1 : 95°C 30 sec, step 2: 95 °C 30 sec, step 3: 55 °C 1 min. step 4: 68 °C 12 min. Steps 2 to 4 were repeated for 12 cycles. TABLE 1 Mutants of TeNT Re constructed
- Step 1 95°C 30 sec.
- step 2 95 °C 30 sec.
- step 3 55 °C 1 min
- step 4 68 °C 18 min. Steps 2 to 4 were repeated
- DNA sequencing The DNA sequence of the entire insert of pKSl encoding HC and of all mutants in the regions altered was determined by automated DNA sequencing.
- cell pellets were resuspended in 10 ml of buffer A (300 mM NaCl, 50 mM NaH 2 P0 4 , pH 8.0) containing lysozyme (1 mg/ml) (Roche Molecular Biochemicals) and 10 mM imidazole (Sigma, Dorset, UK).
- buffer A 300 mM NaCl, 50 mM NaH 2 P0 4 , pH 8.0
- lysozyme (1 mg/ml)
- 10 mM imidazole 10 mM imidazole
- His-tagged proteins were eluted by application of elution buffer (buffer A containing 250 mM imidazole). The protein concentration of the eluted fractions was monitored by measurement at OD 280 . Peak fractions were pooled and dialysed in buffer A, and protein concentration was measured using a Micro BCA protein assay (Pierce, Chester, UK). Between 20 and 32 mg of purified protein was obtained per litre of bacterial culture.
- Biotinylation of HC protein was carried out using the EZ-Link Sulfo-NHS-LC- biotinylation kit (Pierce).
- ELISA plates (Life Technologies. Paisley, UK) were coated with 10 ⁇ g/ml bovine gangliosides GTl b (Sigma.
- GTlb binding activity of mutant proteins (Table 2) is expressed as a percentage of binding of wild-type He protein, and was calculated from the concentration of protein required to give an optical density at 490nm of 1.5, which represents half maximal binding of wild-type He protein.
- Negative controls for non-specific binding included incubation of cells with all reagents except either He protein or primary antibody.
- a variation of the direct binding assay was performed as follows. Coating of plates with gangliosides and blocking was as in the direct assay, and all subsequent incubations were at 37°C in 50 ⁇ l volumes. All washes were for 3 min in PBS/T and repeated three times. Proteins and secondary antibodies were diluted in PBS/TB. A constant amount of biotinylated His-tagged He (prepared as described above) at a concentration of 340 ⁇ g/ml in a volume of 25 ⁇ l was mixed with 25 ⁇ l of test protein at decreasing concentrations (highest concentration of 500 ⁇ g/ml).
- N18 RE-105 cells (ECACC number 881 12301) were cultured in DMEM (Life Technologies) supplemented with 4 mM glutamine (Sigma), 10% FBS and lOOu penicillin, 100 ⁇ g/ml streptomycin (Life Technologies).
- DMEM Dulbecco's modified Eagle's medium
- FBS FBS
- lOOu penicillin 100 ⁇ g/ml streptomycin
- 3 x IO 4 cells in 0.5 ml were plated in each well of an 8 well LabTek chambered slide (Life Technologies) pretreated overnight with 5 ⁇ g/ml poly-L-lysine. Cells were fixed in 4%o paraformaldehyde in PBS for 10 minutes at room temperature. All subsequent incubations were carried out at 4°C.
- Rat spinal cord motoneurons were purified from El 4 rat embryos as previously described. Briefly, ventral spinal cords were dissected, dissociated with 0.025% trypsin (GIBCO- BRL. USA) for 10 minutes at 37 °C and triturated. Cells were centrifuged through a BSA cushion and then tlirough a metrizamide density gradient.
- the interphase and pellet cells were collected tlirough a BSA cushion and resuspended in 50 ⁇ l of phosphate-buffered saline (PBS) with 0.5% BSA (PBS-BSA) plus 50 ⁇ l of mouse anti-rat p75 hybridoma supernatant, which recognises the p75 low affinity nerve growth factor (NGF) receptor specifically expressed by rat motoneurons at E14.
- PBS phosphate-buffered saline
- PBS-BSA BSA
- NGF nerve growth factor
- Cells were incubated with the p75 hybridoma supernatant at 12°C for 15 minutes, washed with PBS-BSA and centrifuged through a BSA cushion.
- the pellet was resuspended in 80 ⁇ l of PBS-BSA and incubated with 20 ⁇ l of goat anti-mouse IgG magnetic microbeads (Miltenyi Biotec, Bergisch -26-
- Cultures were maintained in a humidified 7.5% C0 2 incubator at 37°C in Neurobasal medium (Life Technologies Gibco- BRL, USA) containing B27 supplement (Gibco-BRL, USA), 2% horse serum, 0.5 mM L- glutamine, 25 ⁇ M 2-mercaptoefhanol (Fluka, UK), 10 ng/ml rat ciliary neurotrophic factor and 100 pg/ml rat glial cell line-derived neurotrophic factor (both from R&D systems, USA). L-glutamate (25 ⁇ M) was added to the medium for the first four days in culture.
- mice 10 week old B6D2F1 mice were obtained from Harlan-Olac and were anaesthetised by intramuscular injection with Vetalar (l OOmg/ml) and Rompun (20 mg/ml) in a 2:1 ratio.
- mice Whilst under general anaesthesia, groups of three mice were injected in the tongue with 22 ⁇ l of PBS or PBS containing 70 - 85 ⁇ g protein using a 25 ⁇ l Hamilton syringe with a 33 gauge needle. All animals recovered quickly and were left for 24 hrs to allow the injected protein to be transported to the brainstem. The mice were killed by transcardiac perfusion with PBS, followed by 4% paraformaldehyde in PBS whilst under deep anaesthesia. Brains were dissected and post-fixed for at least 1 hour in 4% formaldehyde before being transferred to 15% sucrose/PBS at 4°C for at least 16 lus. In experiment 1 (Fig. 6, panels a-c), brains were mounted in Tissue-Tek before sectioning into 20 ⁇ m slices using a cryostat. In experiment 2 (Fig. 6, panels d-h), brains were frozen in liquid nitrogen before sectioning.
- Sections were collected on slides which were precoated with poly-L-lysine (Sigma). All subsequent washes were in PBS for 5 minutes and repeated three times. After ringing with a wax pen. the sections were washed. After blocking for 30 mins with PBS/5%) normal swine sera (Dako) sections were incubated with PBS/1% BSA/0.1% Triton X -100 containing rabbit anti-Hc polyclonal antibody diluted 1 :500 for 2 hours. After washing, sections were incubated with biotinylated swine anti-rabbit antibody (Dako) diluted 1 :500 in PBS for 2 hours.
- Dako biotinylated swine anti-rabbit antibody
- mutant M13 ⁇ 131 1-1315
- mutant M13 ⁇ 131 1-1315
- mutant M13 ⁇ 131 1-1315
- mutant M13 ⁇ 131 1-1315
- mutant M13 ⁇ 131 1-1315
- mutant M13 ⁇ 131 1-1315
- mutant M13 ⁇ 131 1-1315
- mutant M13 ⁇ 131 1-1315
- mutant M13 ⁇ 131 1-1315
- mutant M13 ⁇ 131 1-1315
- mutant M13 ⁇ 131 1-1315
- Table 2 To assess the role of individual amino acids within these 10 residues, several mutants containing single amino acid substitutions were constructed and GTlb ganglioside binding measured. These mutant proteins, T1308A. D1309A and E1310A all retained between 80 - 100% of the GTlb binding activity of wild-type He (Table 2).
- a number of other single amino acid substitutions within the ⁇ trefoil domain were also constructed and in all cases the proteins were found to have wild-type levels of GTlb binding activity (data not shown).
- Mutant M28 retained only 5.19% of the GTlb binding activity of wild type He fragment, while mutant M37 displayed an even lower level of binding, having only 1.06% of the activity of wild-type He fragment (Fig. 2 and Table 2).
- deletion of six residues resulted in 5% of wild type ganglioside binding, and deletion of the twelve residues resulted in only 1 % of wild-type binding.
- a second surface exposed loop was identified in the region of D1214 - N1219, connecting two ⁇ sheets within the ⁇ trefoil domain.
- Mutant M58 ( ⁇ D1214 - N1219) exhibited substantially reduced ganglioside GTlb binding, at a level of 0.6 % of wild type He fragment (Fig. 2 and Table 2).
- Example 3 Binding to primary motoneurones is retained by Histidine 1293 mutants and reduced in loop mutants.
- Mutant M37 ( ⁇ H1271-D1282) containing a 12 amino acid deletion in the second loop studied also showed very much reduced binding to mon ⁇ ' spinal cord cells, as did mutant M28 ( ⁇ Q1274-P1279) which contains a 6 amino acid deletion within the same loop region.
- mutant M58. M37 and M28 the reduced binding of gangliosides GTlb (Fig. 2) is consistent with reduced binding to neuronal cells suggesting that residues within loops 1214-1219 and 1274-1279 are important for both ganglioside and cell binding.
- the cell binding activities of the Histidine 1293 mutants were also studied using primary motoneurones. Both the HI 293 A and H1293S mutant proteins appeared to bind as strongly to primary cells as wild-type He protein as.
- mice were injected in the tongue with wild-type or mutant proteins O 01/00839
Abstract
A polypeptide is provided which polypeptide comprises tetanus toxin (TeNT) fragment C, or an immunogenic fragment thereof, which tetanus toxin fragment C, or immunogenic fragment thereof comprises a mutation in a loop region, which mutation results in: a reduction in the binding of the tetanus toxin fragment C, or immunogenic fragment thereof, to gangliosides; and/or a reduction in the binding of the tetanus toxin fragment C, or immunogenic fragment thereof, to primary motoneurones; and/or a reduction in the ability of the tetanus toxin fragment C, or immunogenic fragment thereof, to undergo retrograde transport.
Description
_μ
TETANUS TOXIN POLYPEPTIDES
Field of the invention
This invention relates to polypeptides derived from fragment C of the tetanus toxin and their use in vaccine compositions.
Background to the invention
Tetanus is a highly infectious, worldwide disease caused by the organism Clostridium tetani. Its spores can remain dormant for indefinite periods in house dust and soil which are the prime sources of infection for open wounds. Contaminated animal faeces are also responsible for the spread of the disease and may further contaminate previously uninfected locales.
Tetanus infection is always a risk for the wounded and is usually associated with great pain and may even lead to death. Thus, in the nineteenth century, when the causative agent was discovered to be a bacterium, great effort was devoted to the development of an effective vaccine. The first successful vaccination in human subjects was carried out in 1926, when the vaccine used comprised crude tetanus toxin treated to render it atoxic.
Tetanus toxin provided the target for the first vaccine as it had already been discovered that symptoms are not due to the bacterium infecting host cells but rather by a potent neurotoxin released upon lysis of the bacterial cells.
In vivo, a single (parent) peptide is synthesised which comprises both light and heavy chains. On lysis of the bacterial cell, an endogenous protein cleaves the peptide between a preexisting disulphide bridge to give two peptide chains linked by a disulphide bridge.
Papain cleaves the heavy chain to give a fragment B (100 kDa) consisting of the light chain and part of the heavy chain, and a fragment C (50 kDa). consisting of the remainder of the heavy chain. It has been shown that both fragments are capable of providing protection but
may be associated with residual toxicity that would be due to contamination with uncleaved toxin.
Tetanus toxin (TeNT) is a member of the family of clostridial neurotoxins (CNTs) which includes the botulinum toxins (BoNTs). CNTs inhibit neurotransmitter release from presynaptic neuronal cells by proteolytic cleavage of proteins involved in the fusion of synaptic vesicles with the cell membrane. This cleavage is catalysed by the 50 kDa L-chain of CNTs which encodes a zinc dependent metaloprotease. The overall structural and functional properties of the CNTs are very similar, having a similar sub-unit structure and 30-40% amino acid identity (Minton, 1995). In contrast to BoNTs which remain within the peripheral nervous system, TeNT is trafficked to the central nervous system by retrograde axonal transport followed by trans-synaptic spread into inhibitory interneurons. It is this differential cellular trafficking of TeNT compared to the BoNTs which explains the distinct sites of action of the toxins and therefore the distinct clinical symptoms of the two diseases.
The mechanism whereby TeNT and BoNT bind to sensitive cells has been studied in a variety of in vitro systems including tissue preparations, primary cell cultures and cell lines. These studies, and others, have shown that TeNT and BoNT bind to membrane receptors, and are internalised prior to the cytosolic action of the L-chain of the toxins. The steps involved in binding and trafficking of TeNT are largely uncharacterised, although it appears to involve internalisation through uptake of small synaptic vesicles during vesicle reuptake. The binding of TeNT to neuronal tissue involves the C-terminal 50 kDa domain (He domain, also known as fragment C). as demonstrated by retrograde transport of He in vivo and its ability to bind rat brain membranes and primary neuronal cells and neuroblastoma cell lines in vitro. When added to spinal cord cells. TeNT He fragment blocked uptake of TeNT as shown by inhibition of VAMP-2 cleavage and antagonism of neuromuscular transmission, indicating that the binding of He is functional. The He fragment alone retains the ability to undergo retrograde transport in vivo, and has been used as a carrier of foreign proteins to the CNS.
Since the initial demonstration of TeNT binding to gangliosides, many studies have attempted to characterise binding of CNTs to gangliosides using in vitro and in vivo assays. It is well documented that both TeNT and the isolated He fragment bind gangliosides GDlb and GTlb but not GM1, demonstrating the requirement for poly-sialic acids within the ganglioside for binding. The requirement for gangliosides on cell surfaces was shown by incubation of cultured chromaffm cells with GDlb or GTlb which increased their sensitivity to TeNT and BoNT. Recent experiments involving treatment of primary spinal cord neurons grown in the presence of fumonisin, an inhibitor of ganglioside synthesis, has shown that fumonisin treated cells became insensitive to TeNT, as demonstrated by lack of blockade of potassium - induced stimulation of glycine release and retention of VAMP-reactivity. Furthermore, fumonisin treated cells regained sensitivity to TeNT upon addition of exogenous gangliosides. However, much experimental evidence is inconsistent with gangliosides being the sole receptor for TeNT and BoNTs. For example, both BoNTs and TeNT both bind gangliosides but have different sites of action within the body, polysialoganghosides are not present uniquely on neuronal tissue, and TeNT binding to rat brain membranes and neuronal cell lines is protease sensitive. Thus a dual receptor model, invoking toxin interacting with both gangliosides and protein receptors has been proposed. In support of this model, synaptotagmin II, which is localised in the lumen of small synaptic vesicles, has been identified as a protein receptor for BoNT serotype B, and serotypes A and E. Cross-linking experiments using primary spinal cord motoneurons and NGF-differentiated PC 12 cells have identified a 15 kDa glycoprotein as a possible neuronal receptor for TeNT (Herreros, et al. J. Neurochemsitry in press). This receptor binds only to the carboxy terminal half of the He domain of TeNT.
Existing licensed vaccines are based on the inactivated toxin obtained from lysed C. tetani cells. To obtain sufficient toxin requires large cell-cultures which tends to give rise to toxin being contaminated with cell debris. The resulting toxin is rendered atoxic (toxoided) by treatment, usually with formaldehyde, but may also be toxoided with glutaraldehyde. However, while rendering the toxin harmless, either treatment may also lead to conjugation of the toxin with cell contaminants, which in turn may lead to possible adverse clinical reactions.
WO 01/00839 .4. PCT/GBOO/02428
The structural gene for tetanus toxin has been cloned and sequenced (Fairweather et al.. 1986) and this has enabled the production of recombinant TeNT. Recombinant vaccines based on the fragment C of TeNT have been described in the art (see for example WO-A- 9015871 and EP-A-209281). However, such vaccines retain ganglioside binding activity. Although there is no conclusive evidence that ganglioside binding is associated with toxicity in immunised individuals, it would be desirable to obtain a TeNT polypeptide with reduced ganglioside binding activity.
Studies of the ganglioside binding properties of the He fragment employing deletion mutants expressed in E.coli have shown that some mutants lacking the N-terminal region of He could still bind gangliosides and neuronal cells, but those lacking carboxy terminal amino acids were defective in binding. The studies by Halpern et al (Halpern and Loftus. 1993) suggested an essential role for the carboxy terminal 10 amino acids (residues 1306- 1315) of He in both ganglioside and neuronal cell binding. Studies in which He was bound to a GTlb ganglioside photoaffinity ligand revealed modification of His-1293 within the carboxy-terminal 34 amino acid peptide of He (1282 - 1315) (Shapiro et al, 1997). This result, taken together with inhibition studies using unlabelled GTlb ganglioside. suggested the 34 amino acid peptide of He may be sufficient for binding to gangliosides GTlb.
Mutant molecules were produced in E.coli, purified and assayed in ganglioside binding, cell binding and in vivo retrograde transport assays. Our results identify specific residues that are required for ganglioside binding, and identify certain mutants with reduced ganglioside binding but which still retain the ability to bind primary neuronal cells and undergo retrograde axonal transport.
Summary of the Invention
We have constructed a series of site-directed mutants of TeNT, using the structural information provided by the three dimensional structure reported recently (Umland et al, 1997). Mutant molecules were produced in E.coli. purified and assayed in ganglioside binding, cell binding and in vivo retrograde transport assays. Our results confirm a role for His 1293 in ganglioside binding. However, we have also now identified other regions of
WO 01/00839 . PCT/GBOO/02428
the TeNT fragment C required for binding gangliosides, deletion of which leads to a greater reduction in ganglioside binding than the results obtained for His 1293 alone. Typically, the regions are loop regions which connect two sections of β sheet. Our results also identify certain mutants with reduced ganglioside binding but which still retain the ability to bind primary neuronal cells and undergo retrograde axonal transport.
Accordingly, the present invention provides a polypeptide comprising tetanus toxin (TeNT) fragment C, or an immunogenic fragment thereof, which tetanus toxin fragment C, or immunogenic fragment thereof comprises a mutation in a loop region, which mutation results in a reduction in the binding of the tetanus toxin fragment C, or immunogenic fragment thereof, to gangliosides.
The present invention also provides a polypeptide comprising tetanus toxin (TeNT) fragment C, or an immunogenic fragment thereof, which tetanus toxin fragment C. or immunogenic fragment thereof comprises a mutation in a loop region, which mutation results in a reduction in the binding of the tetanus toxin fragment C, or immunogenic fragment thereof, to primary motoneurones.
The present invention also provides a polypeptide comprising tetanus toxin (TeNT) fragment C, or an immunogenic fragment thereof, which tetanus toxin fragment C. or immunogenic fragment thereof comprises a mutation in a loop region, which mutation results in a reduction in the ability of the tetanus toxin fragment C, or immunogenic fragment thereof, to undergo retrograde transport.
Preferably the mutation results in a reduction in the binding of the tetanus toxin fragment C (or immunogenic fragment thereof) to gangliosides and a reduction in the binding to primary motoneurones and/or a reduction in the ability to undergo retrograde transport.
Preferably said loop region is present in the full length wild type sequence between two β sheets. More preferably said loop region is selected from amino acid residues 1214 to 1219 and 1271 to 1282 of the amino acid sequence of TeNT fragment C.
Preferably said mutation is at least one deletion, more preferably at least one deletion selected from Δ1214 to 1219, Δ1274 to 1279 and Δ1271 to 1282 of the amino acid sequence of TeNT fragment C.
The present invention further provides a polynucleotide encoding a polypeptide of the invention.
The present invention also provides vectors comprising a polynucleotide encoding a polypeptide of the invention operably linked to a regulatory sequence. Preferably the regulatory sequence allows expression of the polypeptide in a host cell. Typically the host cell is a bacterium, or a cell of an animal, more preferably a mammal, including primates and humans.
The polypeptides, polynucleotides and vectors of the present invention may be used in the prevention (or reduction in susceptibility to), or treatment of, Clostridium tetani infections. Thus, in a further aspect, the present invention provides a pharmaceutical composition comprising a polypeptide, polynucleotide or vector of the invention together with a pharmaceutically acceptable carrier or diluent.
The present invention also provides a method of treating or preventing C. tetani infection in a human or animal which comprises administering to the human or animal an effective amount of a polypeptide, polynucleotide or vector of the invention.
The present invention further provides a polypeptide of the present invention for use in therapy, such as the prevention (or reduction in susceptibility to), or treatment of, C. tetani infections. Also provided is the use of a polypeptide of the invention in the manufacture of a medicament for use in the prevention (or reduction in susceptibility to), or treatment of. C. tetani infections.
In another aspect, the invention provides the use of a polypeptide. polynucleotide or vector of the invention in a method for producing antibodies which recognise epitopes within a TeNT polypeptide. For example, the present invention provides a method for producing
antibodies which recognise epitopes within a TeNT polypeptide which method comprises administering a polypeptide, a polynucleotide or a vector of the invention to a mammal.. Such antibodies produced by the various methods known in the art may be used in a method of treating C. tetani infection in a human or animal which comprises administering to a human or animal an effective amount of an antibody produced by the above method of the invention.
In a further aspect, the invention provides a method for reducing the binding affinity of a TeNT fragment C polypeptide for gangliosides which method comprises modifying one or more amino acid residues present in a surface-exposed loop region of the polypeptide. Also provided is a polypeptide produced by said method.
Detailed Description of the Invention
Although in general the techniques mentioned herein are well known in the art, reference may be made in particular to Sambrook et al., Molecular Cloning, A Laboratory Manual (1989) and Ausubel et al., Current Protocols in Molecular Biology (1995), John Wiley & Sons, Inc.
A, TeNT Polvpeptides
The structural gene for tetanus toxin has been cloned and sequenced (Fairweather et al, 1986; Eisel et al., 1986 (also database accession No. BTCLTN and g69647)). The amino acid sequence is provided herein for reference. Fragment C is a 50 kDa polypeptide generated by papain cleavage and comprises or substantially corresponds to the 451 amino acids at the C-terminus. The terms "fragment C" and "He" are used interchangeably herein. It is to be understood that although the description below adopts the amino acid numbering based on the sequence of tetanus toxin described herein, the present invention is equally applicable to fragment C variants found in other strains of C. tetani (which may have slightly different amino acid numbering).
Polvpeptides of the invention comprise tetanus toxin fragment C or immunogenic
g fragments thereof that have been modified to reduce their ability to bind to gangliosides, and/or their ability to bind primary motoneurones, and/or their ability to undergo retrograde transport. In particular, the polypeptides of the invention comprise mutations in a loop region found between 2 β sheets. The 3D structure of TeNT fragment C has been determined by Umland et al. (1997) the structural coordinates deposited in the Protein Data Bank under reference number laf9. The structural information presented in Umland et al. (1997) (see Figure la in particular) allows the skilled person to identify candidate loop regions. Preferably these loops are exposed on the surface of the molecule. These may then be mutagenised and tested for ganglioside binding using, for example, the binding assays described in the Examples. Two such loops which have been shown to be involved in ganglioside binding are described in the Examples. The first loop consists of approximately amino acids 1214 to 1219 and the second loop consists of approximately amino acids 1271 to 1282.
Mutations in the loop regions may be substitutions, insertions and/or deletions. Preferably the mutations are deletions, more preferably deletions which remove substantially all of a particular loop region. Techniques for modifying amino acids sequences are well known in the art, such as PCR-directed mutagenesis.
It is preferred that mutant TeNT polypeptides of the present invention have less than 50% ganglioside binding activity compared with wild type TeNT, more preferably less than 40. 30. 20 or 10%), most preferably less than 5%. Ganglioside binding activity may. for example, be determined in vitro as described in the examples.
Alternatively, or preferably in addition, it is preferred that mutant TeNT polypeptides of the present invention have less than 50% neuronal cell binding activity compared with wild type TeNT, more preferably less than 40. 30, 20 or 10%. most preferably less than 5%. Neuronal cell binding activity may, for example, be determined as described in the examples.
In addition, it is preferred that mutant polypeptides of the invention retain at least 50% of the immunogenicity of the wild type sequence from which they are derived (i.e. the full
WO 01/00839 .9. PCT/GBOO/02428 length fragment C sequence or immunogenic fragments thereof), more preferably at least 70, 80 or 90%. Immunogenicity may be determined typically by the use of in vitro techniques such as ELISA or Western blotting. Alternatively, or in addition, immunogenicity may be determined in vivo by, for example, immunising animals with a polypeptide of the invention and then either testing sera by ELISA or Western blotting, or by subsequently challenging immunised individuals with active toxin.
In a particularly preferred embodiment, a polypeptide of the invention comprises TeNT fragment C, or an immunogenic fragment thereof, which TeNT fragment C, or immunogenic fragment thereof, comprise a mutation in amino acid residues 1214 to 1219 and/or 1271 to 1282. In particular a polypeptide of the invention comprises TeNT fragment C, or an immunogenic fragment thereof, which TeNT fragment C. or immunogenic fragment thereof, comprises a deletion of amino acid residues 1214 to 1219 and/or at least 1274 to 1279, more preferably 1271 to 1282.
In another preferred embodiment, the polypeptides of the invention further comprise a modification at residue His-1293, preferably a substitution such as His→Ala or His-→ Ser.
Fragments of tetanus toxin fragment C that contain epitopes may also be used in the poKφeptides of the invention. These fragments will comprise at least 5 or 6 amino acids, preferably at least 10 amino acids, more preferably at least 15. 20. 50 or 100 amino acids. Particularly preferred fragments include from about amino acids 943 to 1023. which is a good B-cell epitope, and from about amino acids 946 to 966 which is a good T-cell epitope. All amino acid numbering is with reference to the full-length toxin gene.
The amino acid sequence of tetanus toxin fragment C can be further modified to provide polypeptides of the invention. For example, this may be carried out to enhance the immunogenicity of the polypeptides of the invention. Amino acid substitutions may be made, for example from 1, 2 or 3 to 10. 20 or 30 substitutions provided that the modified polypeptide retains epitopes.
Conservative substitutions may be made, for example according to the Table below.
Amino acids in the same block in the second column and preferably in the same line in the third column may be substituted for each other:
Polypeptides of the invention may further comprise heterologous amino acid sequences, typically at the N-terminus or C-terminus, preferably the N-terminus. Heterologous sequences may include sequences that affect intra or extracellular protein targeting (such as leader sequences). Heterologous sequences may also include sequences that increase the immunogenicity of the polypeptide of the invention and/or which facilitate identification, extraction and/or purification of the polypeptides. Another heterologous sequence that is particularly preferred is a polyamino acid sequence such as polyhistidine which is preferably N-terminal. A polyhistidine sequence of at least 10 amino acids, preferably at least 17 amino acids but fewer than 50 amino acids is especially preferred.
Other heterologous amino acid sequences includes immunogenic sequences from other pathogenic organisms such as bacteria or viruses. Examples include pathogenic E. coli, Neiserria sp., B. pertussis, C. difficile, Salmonella sp., Campylobacter sp., P. falciparum, hepatitis B virus, hepatitis C virus and human papilloma virus. Conveniently, these immunogenic sequences may be inserted into a loop region which it is desired to disrupt (such as amino acids 1214 to 1219).
Polypeptides of the invention are typically made by recombinant means, for example as described below. However they may also be made by synthetic means using techniques well known to skilled persons such as solid phase synthesis. Polypeptides of the invention may also be produced as fusion proteins, for example to aid in extraction and purification.
Examples of fusion protein partners include glutathione-S-transferase (GST), 6xHis, GAL4 (DNA binding and/or transcriptional activation domains) and β-galactosidase. It may also be convenient to include a proteolytic cleavage site between the fusion protein partner and the protein sequence of interest to allow removal of fusion protein sequences, such as a thrombin cleavage site. Preferably the fusion protein will not hinder the function of the protein of interest sequence.
Polypeptides of the invention may be in a substantially isolated form. It will be understood that the protein may be mixed with carriers or diluents which will not interfere with the intended purpose of the protein and still be regarded as substantially isolated. A polypeptide of the invention may also be in a substantially purified form, in which case it will generally comprise the protein in a preparation in which more than 90%o, e.g. 95%. 98% or 99%o of the protein in the preparation is a polypeptide of the invention.
B, Polvnucleotides and vectors.
Polynucleotides of the invention comprise nucleic acid sequences encoding the polypeptides of the invention. Polynucleotides of the invention may comprise DNA or RNA. They may also be polynucleotides which include within them synthetic or modified nucleotides. A number of different types of modification to oligonucleotides are known in the art. These include methylphosphonate and phosphorothioate backbones, addition of acridine or polylysine chains at the 3' and/or 5' ends of the molecule. For the purposes of the present invention, it is to be understood that the polynucleotides described herein may be modified by any method available in the art. Such modifications may be carried out in order to enhance the in vivo activity or life span of polynucleotides of the invention.
Preferred polynucleotides of the invention also include polynucleotides encoding any of the polypeptides of the invention described above. It will be understood by a skilled person that numerous different polynucleotides can encode the same polypeptide as a result of the degeneracy of the genetic code.
Polynucleotides of the invention can be incorporated into a recombinant replicable vector.
The vector may be used to replicate the nucleic acid in a compatible host cell. Thus, in a further embodiment, the invention provides a method of making polynucleotides of the invention by introducing a polynucleotide of the invention into a replicable vector, introducing the vector into a compatible host cell, and growing the host cell under conditions which bring about replication of the vector. The vector may be recovered from the host cell. Suitable host cells include bacteria such as E. coli, yeast, mammalian cell lines and other eukaryotic cell lines, for example insect Sf9 cells.
Preferably, a polynucleotide of the invention in a vector is operably linked to a regulator}' sequence that is capable of providing for the expression of the coding sequence by the host cell, i.e. the vector is an expression vector. The term "operably linked'" refers to a juxtaposition wherein the components described are in a relationship permitting them to function in their intended manner. A regulatory sequence "operably linked" to a coding sequence is ligated in such a way that expression of the coding sequence is achieved under conditions compatible with the control sequences.
Such vectors ma)' be transformed or transfected into a suitable host cell as described above to provide for expression of a polypeptide of the invention. This process may comprise culturing a host cell transformed with an expression vector as described above under conditions to provide for expression by the vector of a coding sequence encoding the polypeptides. and optionally recovering the expressed polypeptides.
The vectors may be, for example, plasmid or virus vectors provided with an origin of replication, optionally a promoter for the expression of the said polynucleotide and optionally a regulator of the promoter. The vectors may contain one or more selectable marker genes, for example an ampicillin resistance gene in the case of a bacterial plasmid or a neomycin resistance gene for a mammalian vector. Vectors may be used in vitro, for example for the production of RNA or used to transfect or transform a host cell. The vector may also be adapted to be used in vivo, for example in a method of gene therapy.
Promoters/enhancers and other expression regulation signals may be selected to be compatible with the host cell for which the expression vector is designed. For example.
prokaryotic promoters may be used, in particular those suitable for use in E. coli strains (such as E. coli HB101). In a particularly preferred embodiment of the invention, an htrA or nirB promoter may be used. When expression of the polypeptides of the invention is carried out in mammalian cells, either in vitro or in vivo, mammalian promoters may be used. Tissue-specific promoters may also be used. Viral promoters may also be used, for example the Moloney murine leukaemia virus long terminal repeat (MMLV LTR), the promoter rous sarcoma virus (RSV) LTR promoter, the SV40 promoter, the human cytomegalovirus (CMV) IE promoter, herpes simplex virus promoters or adenovirus promoters. All these promoters are readily available in the art.
C. Host cells
Vectors and polynucleotides of the invention may be introduced into host cells for the purpose of replicating the vectors/polynucleotides and/or expressing the polypeptides of the invention encoded by the polynucleotides of the invention. Suitable host cells include prokaryotes such as eubacteria, for example E. coli and B. subtilis and eukaryotes such as yeast, insect or mammalian cells.
Vectors/polynucleotides of the invention may be introduced into suitable host cells using a variety of techniques known in the art, such as transfection, transformation and electroporation. Where vectors/polynucleotides of the invention are to be administered to animals, several techniques are known in the art, for example infection with recombinant viral vectors such as retroviruses, herpes simplex viruses and adenoviruses. direct injection of nucleic acids and biolistic transformation.
D. Protein Expression and Purification
Host cells comprising polynucleotides of the invention may be used to express polypeptides of the invention. Host cells may be cultured under suitable conditions which allow expression of the proteins of the invention. Expression of the polypeptides of the invention may be constitutive such that they are continually produced, or inducible, requiring a stimulus to initiate expression. In the case of inducible expression, protein production can be initiated when required by. for example, addition of an inducer
, A
-14- substance to the culture medium, for example dexamethasone or IPTG. Suitable methods for producing tetanus toxin fragment C polypeptides are described in WO-A-9015871 and
EP-A-209281.
Polypeptides of the invention can be extracted from host cells by a variety of techniques known in the art, including enzymatic, chemical and/or osmotic lysis and physical disruption.
Purification of polypeptides may optionally be performed using well known techniques such as affinity chromatography. including immuno affinity chromatography, ion-exchange chromatography and the like. A particularly preferred technique is to express the polypeptide of the invention as a fusion protein with polyhistidine tag (for example 6xHis) and purify cell extracts using Ni-NTA agarose (Qiagen). A variety of other similar affinity chromatography systems based on fusion protein sequences are known in the art.
Polypeptides of the invention may also be produced recombinantly in an in vitro cell-free system, such as the TnT™ (Promega) rabbit reticulocyte system.
Administration
The polypeptides of the invention may be administered by direct injection. Preferably the polypeptides are combined with a pharmaceutically acceptable carrier or diluent to produce a pharmaceutical composition, which may be for human or veterinary use. Suitable carriers and diluents include isotonic saline solutions, for example phosphate-buffered saline. The composition may be formulated for parenteral, intramuscular, intravenous, subcutaneous, intraocular or transdermal administration. Typically, each polypeptide is administered at a dose of from 0.01 to 30 μg/kg body weight, preferably from 0.1 to 10 μg/kg. more preferably from 0.1 to 1 μg/kg body weight. It is also possible to use antibodies prepared using the polypeptides of the invention, as described below, in treating or preventing C. tetani infection. Neutralising antibodies, or fragments thereof which retain specificity for C tetani antigens, can be administered in a similar manner to the polypeptides of the invention.
The polynucleotides of the invention may be administered directly as a naked nucleic acid construct, preferably further comprising flanking sequences homologous to the host cell genome. When the expression cassette is administered as a naked nucleic acid, the amount of nucleic acid administered is typically in the range of from 1 μg to 10 mg, preferably from 100 μg to 1 mg.
Uptake of naked nucleic acid constructs by mammalian cells is enhanced by several known transfection techniques for example those including the use of transfection agents. Example of these agents include cationic agents (for example calcium phosphate and DEAE-dextran) and lipofectants (for example lipofectam™ and transfectam™). Typically, nucleic acid constructs are mixed with the transfection agent to produce a composition.
In a particularly preferred embodiment, a nucleotide of the invention is introduced into an attenuated strain of Salmonella sp. such that a polypeptide of the invention is expressed by the transformed bacterial strain and the live bacteria administered, typically orally, to a patient.
Preferably the polynucleotide or vector of the invention is combined with a pharmaceutically acceptable carrier or diluent to produce a pharmaceutical composition. Suitable carriers and diluents include isotonic saline solutions, for example phosphate- buffered saline. The composition may be formulated for parenteral. intramuscular, intravenous, subcutaneous, intraocular or transdermal administration.
The routes of administration and dosages described are intended only as a guide since a skilled practitioner will be able to determine readily the optimum route of administration and dosage for any particular patient and condition.
R Preparation of Vaccines
Vaccines may be prepared from one or more polypeptides of the invention. The preparation
of vaccines which contain an immunogenic polypeptide(s) as active ingredient(s), is known to one skilled in the art. Typically, such vaccines are prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid prior to injection may also be prepared. The preparation may also be emulsified, or the protein encapsulated in liposomes. The active immunogenic ingredients are often mixed with excipients which are pharmaceutically acceptable and compatible with the active ingredient. Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol, or the like and combinations thereof.
In addition, if desired, the vaccine may contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents, and/or adjuvants which enhance the effectiveness of the vaccine. Examples of adjuvants which may be effective include but are not limited to: aluminum hydroxide, N-acetyl-muramyl-L-tlrreonyl-D-isoglutamine (thr-MDP), N-acetyl-nor-muramyl-L-alanyl-D-isoglutamine (CGP 1 1637. referred to as nor-MDP), N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(T-2'-dipalmitoyl-sn- glycero-3-hydroxyphosphoryloxy)-ethylamine (CGP 19835 A, referred to as MTP-PE), and RIBI. which contains three components extracted from bacteria, monophosphoryl lipid A, trehalose dimycolate and cell wall skeleton (MPL+TDM+CWS) in a 2% squalene/Tween 80 emulsion.
Further examples of adjuvants and other agents include aluminum hydroxide, aluminum phosphate, aluminum potassium sulfate (alum), beryllium sulfate, silica, kaolin, carbon, water-in-oil emulsions, oil-in-water emulsions, muramyl dipeptide, bacterial endotoxin, lipid X, Corynebacterium parvum (Propionobacterium acnes), Bordetella pertussis, polyribonucleotides. sodium alginate, lanolin, lysolecithin, vitamin A, saponin, liposomes. levamisole, DEAE-dextran, blocked copolymers or other synthetic adjuvants. Such adjuvants are available commercially from various sources, for example, Merck Adjuvant 65 (Merck and Company, Inc.. Rahway, N.J.) or Freund's Incomplete Adjuvant and Complete Adjuvant (Difco Laboratories, Detroit, Michigan).
Typically, adjuvants such as Amphigen (oil-in-water). Alhydrogel (aluminum hydroxide), or a mixture of Amphigen and Alhydrogel are used. Only aluminum hydroxide is approved
for human use.
The proportion of immunogen and adjuvant can be varied over a broad range so long as both are present in effective amounts. For example, aluminum hydroxide can be present in an amount of about 0.5% of the vaccine mixture (Al O3 basis). Conveniently, the vaccines are formulated to contain a final concentration of immunogen in the range of from 0.2 to 200 μg/ml, preferably 5 to 50 μg/ml, most preferably 15 μg/ml.
After formulation, the vaccine may be incorporated into a sterile container which is then sealed and stored at a low temperature, for example 4°C. or it may be freeze-dried. Lyophilisation permits long-term storage in a stabilised form.
The effectiveness of an adjuvant may be determined by measuring the amount of antibodies directed against an immunogenic polypeptide containing a TeNT antigenic sequence resulting from administration of this polypeptide in vaccines which are also comprised of the various adjuvants.
The vaccines are conventionally administered parenterally, by injection, for example, either subcutaneously or intramuscularly. Additional formulations which are suitable for other modes of administration include suppositories and. in some cases, oral formulations. For suppositories, traditional binders and carriers may include, for example, polyalkylene glycols or triglycerides; such suppositories may be formed from mixtures containing the active ingredient in the range of 0.5% to 10%. preferably 1% to 2%. Oral formulations include such normally employed excipients as. for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate. sodium saccharine, cellulose, magnesium carbonate, and the like. These compositions take the form of solutions, suspensions, tablets, pills, capsules, sustained release formulations or powders and contain 10% to 95% of active ingredient, preferably 25% to 70%. Where the vaccine composition is lyophilised. the lyophilised material may be reconstituted prior to administration, e.g. as a suspension. Reconstitution is preferably effected in buffer
Capsules, tablets and pills for oral administration to a patient may be provided with an
enteric coating comprising, for example, Eudragit "S", Eudragit "L", cellulose acetate, cellulose acetate phthalate or hydroxypropylmethyl cellulose.
The polypeptides of the invention may be formulated into the vaccine as neutral or salt forms. Pharmaceutically acceptable salts include the acid addition salts (formed with free amino groups of the peptide) and which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids such as acetic, oxalic, tartaric and maleic. Salts formed with the free carboxyl groups may also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine. 2-ethylamino ethanol. histidine and procaine.
G. Dosage and Administration of Vaccines
The vaccines are administered in a manner compatible with the dosage formulation, and in such amount as will be prophylactically and/or therapeutically effective. The quantity to be administered, which is generally in the range of 5 μg to 250 μg of antigen per dose, depends on the subject to be treated, capacity of the subject's immune system to synthesize antibodies, and the degree of protection desired. A preferable range is from about 20 μg to about 40 μg per dose.
A suitable dose size is about 0.5 ml. Accordingly, a dose for intramuscular injection, for example, would comprise 0.5 ml containing 20 μg of immunogen in admixture with 0.5%o aluminum hydroxide.
Precise amounts of active ingredient required to be administered may depend on the judgement of the practitioner and may be peculiar to each subject.
The vaccine may be given in a single dose schedule, or preferably in a multiple dose schedule. A multiple dose schedule is one in which a primary course of vaccination may be with 1-10 separate doses, followed by other doses given at subsequent time intervals required to maintain and or reinforce the immune response, for example, at 1 to 4 months
for a second dose, and if needed, a subsequent dose(s) after several months. The dosage regimen will also, at least in part, be determined by the need of the individual and be dependent upon the judgement of the practitioner.
In addition, the vaccine containing the immunogenic TeNT antigen(s) may be administered in conjunction with other immunoregulatory agents, for example, immunoglobulins.
H. Preparation of antibodies against the polvpeptides of the invention
The immunogenic polypeptides prepared as described above can be used to produce antibodies, both polyclonal and monoclonal. If polyclonal antibodies are desired, a selected mammal (e.g.. mouse, rabbit, goat, horse, etc.) is immunised with an immunogenic polypeptide bearing a TeNT epitope(s). Serum from the immunised animal is collected and treated according to known procedures. If serum containing polyclonal antibodies to a TeNT epitope contains antibodies to other antigens, the polyclonal antibodies can be purified by immunoaffinity chromatography. Techniques for producing and processing polyclonal antisera are known in the art.
Monoclonal antibodies directed against TeNT epitopes in the polypeptides of the invention can also be readily produced by one skilled in the art. The general methodology for making monoclonal antibodies by hybridomas is well known. Immortal antibody- producing cell lines can be created by cell fusion, and also by other techniques such as direct transformation of B lymphocytes with oncogenic DNA, or transfection with Epstein- Barr virus. Panels of monoclonal antibodies produced against TeNT epitopes can be screened for various properties; i.e., for isotype and epitope affinity.
An alternative technique involves screening phage display libraries where, for example the phage express scFv fragments on the surface of their coat with a large variety of complementarity determining regions (CDRs). This technique is well known in the art.
Antibodies, both monoclonal and polyclonal, which are directed against TeNT epitopes are particularly useful in diagnosis, and those which are neutralising are useful in passive
immunotherapy. Monoclonal antibodies, in particular, may be used to raise anti-idiotype antibodies. Anti-idiotype antibodies are immunoglobulins which carry an "internal image" of the antigen of the infectious agent against which protection is desired.
Techniques for raising anti-idiotype antibodies are known in the art. These anti-idiotype antibodies may also be useful for treatment of C. tetani, as well as for an elucidation of the immunogenic regions of C. tetani antigens.
For the purposes of this invention, the term "antibody", unless specified to the contrary, includes fragments of whole antibodies which retain their binding activity for a target antigen. Such fragments include Fv, F(ab') and F(ab')2 fragments, as well as single chain antibodies (scFv). Furthermore, the antibodies and fragments thereof may be humanised antibodies, for example as described in EP-A-239400.
The invention will be described with reference to the following Examples which are intended to be illustrative only and not limiting. The Examples refer to the Figures. Referring to the Figures in more details:
Description of the Figures
Figure 1 is a 3D representation of the structure of tetanus toxin fragment C.
Figure 2 is a graph showing % binding to gangliosides compared with wild type for various TeNT fragment C mutants.
EXAMPLES
METHODS
Bacterial strains and plasmid construction
E. coli strain BL21 (λDE3, ompT, hsdSH (rB-mB-), gal, dcm) was used as the host for the plasmids described below. Plasmid pKSl contains a codon-optimised gene for the expression of the He fragment of TeNT under the control of the T7 promoter. It was created by PCR amplification (Pfu polymerase, Stratagene, Cambridge UK) of a 1357 bp fragment using pTETtac215 (Makoff et al., 1989) as template and the oligonucleotides 5"GAGCATATGAAAAACCTTGAT and 5'CGGATCCTTAGTCGTTGGTCCA which introduce Ndel and BarnWl sites at the 5 ' and 3 * ends of the gene respectively. After blunt end ligation of the PCR product into the vector pCRScript (Stratagene) to form plasmid pJC6, the Ndel - BamHl fragment was purified by agarose gel electrophoresis using a Qiaex II gel purification kit (Qiagen, West Sussex, UK), and sublconed into pET28a (Novagen, Cambridge UK) which had previously been digested with Ndel and BamHl (Roche Molecular Biochemicals, East Sussex, UK). DNA manipulations were performed by standard procedures.
Mutagenesis and DNA sequencing
Mutagenesis was performed using the QuikChange™ site-directed mutagenesis kit (Stratagene). Pairs of complementary oligonucleotides were used to construct mutant He molecules (see Table 1). To create mutants containing single amino acid mutations (Ml 5, M24. M667, M564 and M57), the following cycles were used with pKSl as template DNA: Step 1 : 95°C 30 sec, step 2: 95 °C 30 sec, step 3: 55 °C 1 min. step 4: 68 °C 12 min. Steps 2 to 4 were repeated for 12 cycles.
TABLE 1 Mutants of TeNT Re constructed
To construct molecules containing deletions (M5, M13, M28 and M58) longer extension
times were used with pKSl as template DNA in the following cycles: Step 1 : 95°C 30 sec. step 2: 95 °C 30 sec. step 3: 55 °C 1 min, step 4: 68 °C 18 min. Steps 2 to 4 were repeated
for 18 cycles. To construct mutant M37 and the double mutant M40. identical cycling
conditions were used, but using M28 mutant DNA as a template.
DNA sequencing The DNA sequence of the entire insert of pKSl encoding HC and of all mutants in the regions altered was determined by automated DNA sequencing.
Purification of recombinant His-tagged proteins 250 ml of LB broth containing kanamycin (50 μg/ml) were inoculated with 5 ml of an overnight culture of E. coli BL21 cells containing pKSl or derivatives encoding mutant H
genes. At an OD65o = 0.8, expression of wild type or mutant He protein was induced by the addition of isopropyl-β-D-galactopyranoside (IPTG) to a final concentration of 1 mM. Incubation at 37°C was continued for 3.5 hours, after which cells were recovered by centrifugation at 4000 g for 15 min. Cell pellets were frozen and stored at -20°C. To purify the His-tagged proteins, cell pellets were resuspended in 10 ml of buffer A (300 mM NaCl, 50 mM NaH2P04, pH 8.0) containing lysozyme (1 mg/ml) (Roche Molecular Biochemicals) and 10 mM imidazole (Sigma, Dorset, UK).
Cells were sonicated on ice with a flat tip probe for 4.5 minutes in pulses of 15 sec on, 15 sec off using a 550W sonicator (Ultrasonic Processor XL2020, Heat Systems, New York,
USA). After centrifugation at 13,000 g for 20 min, 500 μl of Ni-NTA agarose resin
(Qiagen) was added and the mixture incubated whilst rotating for 16 h at 4°C. The resin was then centrifuged at 200 g and resuspended in 10 ml buffer A containing 20 mM imidazole. The centriguation and resuspension was repeated twice. The resin was resuspended in 5 ml buffer A and was poured into a disposable plastic column (Biorad,
Herts. UK) and the liquid allowed to drain away. The His-tagged proteins were eluted by application of elution buffer (buffer A containing 250 mM imidazole). The protein concentration of the eluted fractions was monitored by measurement at OD280. Peak fractions were pooled and dialysed in buffer A, and protein concentration was measured using a Micro BCA protein assay (Pierce, Chester, UK). Between 20 and 32 mg of purified protein was obtained per litre of bacterial culture.
Biotinylation of He protein
Biotinylation of HC protein was carried out using the EZ-Link Sulfo-NHS-LC- biotinylation kit (Pierce).
Ganglioside binding in vitro (i) Direct binding assay
Direct binding of proteins to gangliosides was measured as follows. ELISA plates (Life Technologies. Paisley, UK) were coated with 10 μg/ml bovine gangliosides GTlb (Sigma.
Dorset. UK) in 50 μl methanol and allowed to dry overnight. After two washes of 3 min in phosphate buffered saline (PBS) containing 0.05% Tween 20 (PBS/T). 100 μl of blocking
„4
solution (PBS containing 3% BSA (Sigma)) was added, and the plates blocked for 1 hour at 37°C. All subsequent incubations were at 37°C in 50 μl volumes, and all washes were for 3 min in PBS/T and repeated three times. Proteins and primary and secondary antibodies were diluted in PBS/T containing 3% BSA (PBS/TB).
After blocking and washing, plates were incubated for 2 hours with doubling dilutions of wild type His-tagged HC or mutant His-tagged He starting from an initial concentration of 10 μg/ml protein. After washing, rabbit polyclonal anti-He antibody (Fairweather et al.. 1986) diluted 1 :1000 was added for 1 hour. After washing, goat anti-rabbit antibody conjugated to horse radish peroxidase was added as a secondary antibody. Plates were devloped with o-phenylenediamine dihydrochloride (Sigma). The plates were read at 490nm in a Ceres 900 Hdi ELISA reader (Bio-Tek Instruments). Each data point represents the mean of duplicate values after subtraction of the mean value obtained when no protein was added. The GTlb binding activity of mutant proteins (Table 2) is expressed as a percentage of binding of wild-type He protein, and was calculated from the concentration of protein required to give an optical density at 490nm of 1.5, which represents half maximal binding of wild-type He protein.
Negative controls for non-specific binding included incubation of cells with all reagents except either He protein or primary antibody.
(ii) Competition assay
A variation of the direct binding assay was performed as follows. Coating of plates with gangliosides and blocking was as in the direct assay, and all subsequent incubations were at 37°C in 50 μl volumes. All washes were for 3 min in PBS/T and repeated three times. Proteins and secondary antibodies were diluted in PBS/TB. A constant amount of biotinylated His-tagged He (prepared as described above) at a concentration of 340 μg/ml in a volume of 25 μl was mixed with 25 μl of test protein at decreasing concentrations (highest concentration of 500 μg/ml). 50 μl of the mixture of biotinylated Hc/unlabelled protein was added to the ganglioside coated plates, and the plates incubated for 2 hours. The plates were washed again and incubated with streptavidin-HRP (Dako). diluted 1 in
500, for 1 hour. After washing, the plates were developed with ø-phenylenediamine dihydrochloride (OPD, Sigma) and read at 490nm in an ELISA plate reader.
Binding of mutants to NI8 cells N18 RE-105 cells (ECACC number 881 12301) were cultured in DMEM (Life Technologies) supplemented with 4 mM glutamine (Sigma), 10% FBS and lOOu penicillin, 100 μg/ml streptomycin (Life Technologies). One day prior to use in indirect immunofluorescence, 3 x IO4 cells in 0.5 ml were plated in each well of an 8 well LabTek chambered slide (Life Technologies) pretreated overnight with 5 μg/ml poly-L-lysine. Cells were fixed in 4%o paraformaldehyde in PBS for 10 minutes at room temperature. All subsequent incubations were carried out at 4°C. All washes were in PBS containing 0.1% BSA (PBS/B) at 4°C and were repeated 3 times for 3 min. Cells were incubated with wild type or mutant proteins (5 μg/ml) for 2 hours. After washing, cells were incubated for 30 min in PBS/B containing 5% normal swine serum, followed by 30 min with rabbit polyclonal anti He antibody, diluted 1 in 500 in PBS/B containing 5% normal swine serum. The cells were washed again and incubated for 1 hour with FITC-conjugated goat anti- rabbit serum (Dako) diluted 1 in 500 in PBS/B. After washing, cells were mounted in an antifade agent in glycerol/PBS (Citifluor, Agar Scientific. Harlow. UK) and visualised by fluorescent microscopy using a Zeiss 510 confocal microscope.
Purification of rat spinal cord motoneurons
Rat spinal cord motoneurons were purified from El 4 rat embryos as previously described. Briefly, ventral spinal cords were dissected, dissociated with 0.025% trypsin (GIBCO- BRL. USA) for 10 minutes at 37 °C and triturated. Cells were centrifuged through a BSA cushion and then tlirough a metrizamide density gradient. The interphase and pellet cells were collected tlirough a BSA cushion and resuspended in 50 μl of phosphate-buffered saline (PBS) with 0.5% BSA (PBS-BSA) plus 50 μl of mouse anti-rat p75 hybridoma supernatant, which recognises the p75 low affinity nerve growth factor (NGF) receptor specifically expressed by rat motoneurons at E14. Cells were incubated with the p75 hybridoma supernatant at 12°C for 15 minutes, washed with PBS-BSA and centrifuged through a BSA cushion. The pellet was resuspended in 80 μl of PBS-BSA and incubated with 20 μl of goat anti-mouse IgG magnetic microbeads (Miltenyi Biotec, Bergisch
-26-
Gladbach, Germany) for 15 minutes at 12°C. After another centrifugation through a BSA cushion cells were resuspended in 500 μl of PBS-BSA and purified by magnetic cell sorting using a Mini Macs magnet and a large cell separation column (Miltenyi Biotec). Purified motoneurons were seeded on glass coverslips coated with polyornithine and laminin (Sigma, UK) at a density of 40000 cells/coverslip. Cultures were maintained in a humidified 7.5% C02 incubator at 37°C in Neurobasal medium (Life Technologies Gibco- BRL, USA) containing B27 supplement (Gibco-BRL, USA), 2% horse serum, 0.5 mM L- glutamine, 25 μM 2-mercaptoefhanol (Fluka, UK), 10 ng/ml rat ciliary neurotrophic factor and 100 pg/ml rat glial cell line-derived neurotrophic factor (both from R&D systems, USA). L-glutamate (25 μM) was added to the medium for the first four days in culture.
Binding of wild-type and mutant He proteins to primary motoneurones.
Cells on coverslips were cooled to 4°C for 15 minutes and then washed twice with Hanks' solution (20mM Hepes-Na, pH7.4, 0.44mM mM KH2P04. 0.42mM Na2HP04. 5.36mM KCl, 136mM NaCl, 0.81mM MgS04, 1.26mM CaCl2, 6.1mM glucose) before incubation with wt or mutant He at a concentration of 5μg/ml in Hanks/0.1% BSA for 1 hour at 4 °C. After washing twice with Hanks' solution, cells were fixed in 3.7% paraformaldehyde in PBS for 15 minutes at room temperature. After washing twice with PBS. cells were incubated for 20 minutes with 50mM NH4C1 in PBS, washed twice again with PBS and blocked for 1 hour with 2% BSA, 0.25% porcine skin gelatin, 0.2% glycine. 10% foetal calf serum. Cells were washed twice in PBS then incubated for 1 hour with rabbit anti-He polyclonal antiserum diluted 1 in 500 in PBS containing 1% BSA, 0.25% gelatin. After two further washes with PBS, cells were incubated for 30 min with FITC conjugated swine anti-rabbit serum (Dako) diluted 1 in 1000 in PBS. After four washes with PBS, coverslips were mounted on slides in Mowiol 4-88 (Harco), stored at 4°C and were analysed by fluorescence using a Zeiss LSM510 confocal microscope.
Retrograde transport of ild type and mutant He proteins
10 week old B6D2F1 mice were obtained from Harlan-Olac and were anaesthetised by intramuscular injection with Vetalar (l OOmg/ml) and Rompun (20 mg/ml) in a 2:1 ratio.
Whilst under general anaesthesia, groups of three mice were injected in the tongue with 22 μl of PBS or PBS containing 70 - 85 μg protein using a 25μl Hamilton syringe with a 33
gauge needle. All animals recovered quickly and were left for 24 hrs to allow the injected protein to be transported to the brainstem. The mice were killed by transcardiac perfusion with PBS, followed by 4% paraformaldehyde in PBS whilst under deep anaesthesia. Brains were dissected and post-fixed for at least 1 hour in 4% formaldehyde before being transferred to 15% sucrose/PBS at 4°C for at least 16 lus. In experiment 1 (Fig. 6, panels a-c), brains were mounted in Tissue-Tek before sectioning into 20μm slices using a cryostat. In experiment 2 (Fig. 6, panels d-h), brains were frozen in liquid nitrogen before sectioning.
Immuno staining of t and mutant He in the hypoglossal nucleus
Sections were collected on slides which were precoated with poly-L-lysine (Sigma). All subsequent washes were in PBS for 5 minutes and repeated three times. After ringing with a wax pen. the sections were washed. After blocking for 30 mins with PBS/5%) normal swine sera (Dako) sections were incubated with PBS/1% BSA/0.1% Triton X -100 containing rabbit anti-Hc polyclonal antibody diluted 1 :500 for 2 hours. After washing, sections were incubated with biotinylated swine anti-rabbit antibody (Dako) diluted 1 :500 in PBS for 2 hours. After washing again, sections were incubated with peroxidase- conjugated avidin diluted 1 :500 in PBS for 2 hours. Sections were washed and developed with diaminobenzidine (0.05%) in PBS with 0.04% NiCl2 and 0.01% H202 for 10 minutes. Sections were washed in distilled water, counterstained with 1% neutral red. dehydrated and mounted. Slides were stored at -50°C before photography.
Example 1 - Roles of N and C termini of He in ganglioside binding
An inspection of the 3-D structure of the He fragment TeNT (Umland et al.. 1997) reveals two domains, an N-terminal jelly roll domain and a C-terminal β trefoil domain, linked by a single chain (Figure 1). These domains each consist largely of β sheets joined by loops which protrude from the molecule.
Our previous study analysed neuronal cell binding of a number of malE-Hc fusion proteins. Proteins M1453 containing the entire Hc domain of TeNT (K865 - D1315) and M338 (N944 - D1315) bound avidly to primary dorsal root ganglion cells, whereas Ml 321 (K865
- H1271) displayed no binding in this assay. In this study, it was found that both M1453 and M338 bound equally well to GTlb gangliosides, whereas M1321 had no detectable binding. These results confirm that the first 80 amino terminal residues of He, absent in M338, are not essential for ganglioside or cell binding while the carboxy terminal domain, absent in M1321, appears to be essential for these activities.
Deletion mutagenesis of the C-terminal region of He identified VI 306 - D1315 as important for ganglioside binding and neuronal cell binding. This peptide originates within the β trefoil structure, and terminates in the cleft dividing this domain and the lectin like domain (Fig. 1). To analyse further the regions of He involved in ganglioside GTlb binding, a series of mutant He proteins was constructed as His-tag fusions (Table 2). Mutant His-tagged proteins were expressed in E.coli BL21 and purified using nickel agarose affinity chromatography. Our first series of mutants was constructed in the C terminal region of He. Mutant M5, lacking the 10 C terminal residues (Δ1306-1315). displayed GTlb binding at 80% of the wild-type level, while mutant M13 (Δ131 1-1315) had levels of binding indistinguishable from wild-type He (Table 2). To assess the role of individual amino acids within these 10 residues, several mutants containing single amino acid substitutions were constructed and GTlb ganglioside binding measured. These mutant proteins, T1308A. D1309A and E1310A all retained between 80 - 100% of the GTlb binding activity of wild-type He (Table 2). A number of other single amino acid substitutions within the β trefoil domain were also constructed and in all cases the proteins were found to have wild-type levels of GTlb binding activity (data not shown).
Example 2 - Mutants of He displaying decreased ganglioside binding
In order to identify other residues of the He molecule involved in ganglioside GTlb binding, we chose to investigate the regions comprising the loops joining the β sheets within the carboxy terminal β trefoil domain. These regions are surface exposed and are most likely to interact with ligands on the surface of cells. Mutants were constructed which lacked either six residues, M28 (ΔQ1274 - PI 279). or twelve residues. M37 (ΔH1271 - D1282). of a loop joining two β sheets within the β trefoil domain (Fig. 1). Purified proteins were assayed for ganglioside GTlb binding. Mutant M28 retained only 5.19% of
the GTlb binding activity of wild type He fragment, while mutant M37 displayed an even lower level of binding, having only 1.06% of the activity of wild-type He fragment (Fig. 2 and Table 2). In other words, deletion of six residues resulted in 5% of wild type ganglioside binding, and deletion of the twelve residues resulted in only 1 % of wild-type binding.
A second surface exposed loop was identified in the region of D1214 - N1219, connecting two β sheets within the β trefoil domain. Mutant M58 (ΔD1214 - N1219) exhibited substantially reduced ganglioside GTlb binding, at a level of 0.6 % of wild type He fragment (Fig. 2 and Table 2).
TABLE 2: Ganglioside binding of mutant He proteins
These results were confirmed using a competition assay as described in the methods section. Thus our results demonstrate that a deletion in either one of two loops joining β sheets in the TeNT He molecule dramatically reduces the ability of the molecule to bind to gangliosides.
Photoaffinity labelling of TeNT with derivatised gangliosides have shown His-1293 to be involved in ganglioside binding. We tested the role of this residue in binding by mutation to both Serine and Alanine. Both these mutants showed decreased binding (to 43% and 15% of wild type respectively) confirming the importance of His 1293 in binding. His 1293 is spatially near the His- 1271 to Asp 1282 loop we have now shown also to be involved in binding. A double mutant, comprising His 1293 - Ser and ΔHis 1271 to Asp 1282 was constructed and found to exhibit markedly reduced binding (4.2% of wild-type levels) (see Table 2 and Figure 2).
We also investigated the capacity of the mutant He proteins to bind to N18 neuronal cells (see methods).
Example 3 - Binding to primary motoneurones is retained by Histidine 1293 mutants and reduced in loop mutants.
To determine whether the ganglioside binding activity of mutant He proteins correlated with binding to neuronal cells, we tested the binding of the proteins to primary rat spinal cord motoneurons. Binding was visualised using a polyclonal anti-Hc antibody and fluorescent labelled secondary antibody. Both wild type He and mutant M5 (ΔV1306- D1315) proteins were shown to bind strongly to primary spinal cord motoneurons. These results suggest that the carboxy terminal ten residues of He are not essential for binding to neuronal cells. In contrast, the ability of loop mutant M58 (ΔD1214 - N1219) to bind to spinal cord motoneurons was very much reduced, as visualised by the very weak staining of primary motoneurons. Mutant M37 (ΔH1271-D1282) containing a 12 amino acid deletion in the second loop studied also showed very much reduced binding to primar}' spinal cord cells, as did mutant M28 (ΔQ1274-P1279) which contains a 6 amino acid deletion within the same loop region. For mutants M58. M37 and M28 the reduced binding of gangliosides GTlb (Fig. 2) is consistent with reduced binding to neuronal cells suggesting that residues within loops 1214-1219 and 1274-1279 are important for both ganglioside and cell binding.
The cell binding activities of the Histidine 1293 mutants were also studied using primary motoneurones. Both the HI 293 A and H1293S mutant proteins appeared to bind as strongly to primary cells as wild-type He protein as. judged by strong staining pattern obtained. This is in contrast to the results obtained with ganglioside GTlb, where a reduction in binding activity to 12 - 43%) of wild-type levels was clearly observed (Table 2). Thus a large decrease in ganglioside GTlb binding does not reduce the ability of these mutant proteins to bind to primary neuronal cells. The ganglioside binding, cell binding and retrograde transport (see below) activities of selected mutants are summarised in Table
TABLE 3 : Binding and transport properties of mutants of TeNT He in this study
The properties of selected mutant He proteins are summarised and compared to wild-type protein, n.d., not determined.
Example 4 - Retrograde transport activity is retained by Histidine 1293 mutants but abolished in loop mutants.
As a functional test of the biological activity of our mutants, we investigated the ability of proteins to undergo retrograde transport in the mouse from peripheral neurons to the central nervous system. This is a well-recognised property of the He fragment of TeNT. and reflects the ability of TeNT to be transported to higher centres of the central nervous system. For this assay, mice were injected in the tongue with wild-type or mutant proteins
O 01/00839
and the ability of the proteins to be transported to the hypoglossal nucleus within the brainstem was visualised. Wild-type He protein was detected in the hypoglossal nucleus after 24 hours, while in contrast mutant M28 (ΔQ1274 -PI 279) could not be detected, indicating this mutant is defective in retrograde transport. The lack of staining of M28 was similar to that seen with the negative control, where PBS was used. This result is consistent with the reduced ganglioside binding activity of M28 (Fig. 2 and Table 2) and the reduced binding to primary motoneuron cells.
In a second experiment, we found that the loop mutant M58 (Δ1214-1219) also failed to undergo retrograde transport, the lack of staining being similar to the uninjected mouse.
These results suggest that residues 1274-1279 and 1214-1219 are essential for retrograde transport, consistent with their role in ganglioside binding and cell binding. Positive staining was obtained with the C terminal mutant M5 (ΔV1306 -D1315) and wild-type He protein indicating that the carboxy terminal 10 residues of He are not essential for ganglioside binding, cell binding or retrograde transport. Finally, the role of Histidine
1293 in retrograde transport was also examined. HI 293 A protein underwent retrograde transport as visualised by staining of the hypoglossal nucleus, suggesting that Histidine
1293 is not absolutely required for retrograde transport activity. Similar results showing retrograde transport of another Histidine 1293 mutant (H1293S) were obtained by P. Fishman (pers. comm).
References
Fairweather et al., 1986, J. Bacteriol, 165, p21-27. Eisel, et al., 1986, Embo J. 5(10): 2494-2502. Makoff, A. j., S. P. Ballantine, A. E. Smallwood, and N. F. Fairweather, 1989, Bio/Technology. 7: 1043-1046.
Halpern and Loftus, 1993, J. Biol. Chem. 268: 1 1 188-1 1192. Shapiro et al, 1997, J. Biol. Chem 272: 30080-30386. Umland et al, 1997, Nature Struct. Biol. 4:788-791. Minton, N. P. 1995. Molecular genetics of clostridial neurotoxins, p. 161-194. In C. Montecucco (ed.), Clostridial neurotoxins. Springer, New York.
Claims
1. A polypeptide comprising tetanus toxin (TeNT) fragment C, or an immunogenic fragment thereof, which tetanus toxin fragment C, or immunogenic fragment thereof comprises a mutation in a loop region, which mutation results in: a reduction in the binding of the tetanus toxin fragment C, or immunogenic fragment thereof, to gangliosides; and/or a reduction in the binding of the tetanus toxin fragment C, or immunogenic fragment thereof, to primary motoneurones; and/or a reduction in the ability of the tetanus toxin fragment C, or immunogenic fragment thereof, to undergo retrograde transport.
2. A polypeptide according to claim 1 wherein said loop region is selected from amino acid residues 1214 to 1219 and 1272 to 1282 of the amino acid sequence of TeNT fragment C.
3. A polypeptide according to claim 1 or 2 wherein said mutation is at least one deletion.
4. A polypeptide according to claim 3 wherein said deletion is selected from Δ1214 to 1219. Δ1274 to 1279 and Δ1271 to 1282 of the amino acid sequence of TeNT fragment C.
5. A polynucleotide encoding a polypeptide according to any one of claims 1 to 4.
6. A vector comprising a polynucleotide according to claim 5 operably linked to a regulatory sequence permitting expression of the polynucleotides in a host cell.
7. A host cell comprising a vector according to claim 6.
8. A host cell according to claim 7 which is a bacterium.
9. A pharmaceutical composition comprising a polypeptide according to any one of claims 1 to 4, a polynucleotide according to claim 5 or a vector according to claim 6 together with a pharmaceutically acceptable carrier to diluent.
10. A vaccine composition comprising a polypeptide according to any one of claims 1 to 4, a polynucleotide according to claim 5 or a vector according to claim 6 together with a pharmaceutically acceptable carrier to diluent.
11. A method of treating or preventing or reducing the susceptibility to C. tetani infection in a human or animal which comprises administering to the human or animal an effective amount of a polypeptide according to any one of claims 1 to 4, a polynucleotide according to claim 5 or a vector according to claim 6.
12. Use of a polypeptide according to any one of claims 1 to 4, a polynucleotide according to claim 5 or a vector according to claim 6 in a method for producing antibodies which recognise epitopes within a TeNT polypeptide.
13. A method for producing antibodies which recognise epitopes within a TeNT polypeptide which method comprises administering a polypeptide according to any one of claims 1 to 4, a polynucleotide according to claim 5 or a vector according to claim 6 to a mammal.
14. A method of treating C. tetani infection in a human or animal which comprises administering to a human or animal an effective amount of an antibody produced according to claim 12 or 13.
15. A method for reducing the binding affinity of a TeNT fragment C polypeptide for gangliosides which method comprises modifying one or more amino acid residues present in a surface-exposed loop region of the polypeptide.
16. A polypeptide produced by the method of claim 15.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9914861 | 1999-06-25 | ||
GBGB9914861.1A GB9914861D0 (en) | 1999-06-25 | 1999-06-25 | Tetanus toxin polypeptides |
PCT/GB2000/002428 WO2001000839A1 (en) | 1999-06-25 | 2000-06-23 | Tetanus toxin polypeptides |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1196584A1 true EP1196584A1 (en) | 2002-04-17 |
Family
ID=10856045
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP00940598A Withdrawn EP1196584A1 (en) | 1999-06-25 | 2000-06-23 | Tetanus toxin polypeptides |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1196584A1 (en) |
JP (1) | JP2003503059A (en) |
AU (1) | AU5551200A (en) |
GB (1) | GB9914861D0 (en) |
WO (1) | WO2001000839A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9617671D0 (en) | 1996-08-23 | 1996-10-02 | Microbiological Res Authority | Recombinant toxin fragments |
US8012491B2 (en) | 1996-08-23 | 2011-09-06 | Syntaxin, Ltd. | Recombinant toxin fragments |
US7192596B2 (en) | 1996-08-23 | 2007-03-20 | The Health Protection Agency Ipsen Limited | Recombinant toxin fragments |
US11491239B2 (en) * | 2017-12-15 | 2022-11-08 | The Medical College Of Wisconsin, Inc. | Modified clostridial neurotoxins as vaccines and conjugate vaccine platforms |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8516442D0 (en) * | 1985-06-28 | 1985-07-31 | Wellcome Found | Cloned antigen |
WO1994000487A1 (en) * | 1992-06-30 | 1994-01-06 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Peptide which produces protective immunity against tetanus |
-
1999
- 1999-06-25 GB GBGB9914861.1A patent/GB9914861D0/en not_active Ceased
-
2000
- 2000-06-23 JP JP2001506831A patent/JP2003503059A/en active Pending
- 2000-06-23 EP EP00940598A patent/EP1196584A1/en not_active Withdrawn
- 2000-06-23 WO PCT/GB2000/002428 patent/WO2001000839A1/en not_active Application Discontinuation
- 2000-06-23 AU AU55512/00A patent/AU5551200A/en not_active Abandoned
Non-Patent Citations (1)
Title |
---|
See references of WO0100839A1 * |
Also Published As
Publication number | Publication date |
---|---|
GB9914861D0 (en) | 1999-08-25 |
WO2001000839A1 (en) | 2001-01-04 |
AU5551200A (en) | 2001-01-31 |
JP2003503059A (en) | 2003-01-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4283872B2 (en) | Microbial protein, microorganisms producing this protein, and use of the protein in vaccines and tuberculosis detection | |
EA006232B1 (en) | Streptococcus antigens | |
KR20000049101A (en) | Compounds and Methods For Immunotherapy And Diagonisis of Tuberculosis | |
JP2002503683A (en) | Compounds and methods for immunotherapy and diagnosis of tuberculosis | |
AU735112B2 (en) | Novel polynucleotides and polypeptides in pathogenic mycobacteria and their use as diagnostics, vaccines and targets for chemotherapy | |
US10166279B2 (en) | Vaccine | |
AU744733B2 (en) | Neisseria lactoferrin binding protein | |
EP1196584A1 (en) | Tetanus toxin polypeptides | |
JP2005532789A (en) | P4 protein variant of non-typeable Haemophilus influenzae with reduced enzymatic activity | |
EP0368819A1 (en) | Expression of the binding subunit of cholera toxin with the aid of foreign promoters and/or leader sequences | |
EP1029054A1 (en) | Hp90: host membrane receptor for pathogenic bacteria, encoded by the bacterial tir gene | |
US6335182B1 (en) | Recombinant Haemophilus influenzae adhesin proteins | |
US20030086946A1 (en) | Antigenic, non-toxic mutants of Clostridium septicum alpha toxin and vaccines, antibodies, sera, and methods of treatment therewith | |
US20060160159A1 (en) | Identification of actinobacillus actinomycetemcomitans antigens for use in the diagnosis, treatment, and monitoring of periodontal diseases | |
US6054134A (en) | Haemophilus adhesin protein | |
US6218147B1 (en) | Haemophilus adhesin protein | |
US20030049265A1 (en) | Heliobacter pylori antigen | |
KR20010044842A (en) | Peptide fragments of cholera toxin B or enterotoxin B as vaccine adjuvants | |
NZ548093A (en) | Use of neisseria meningitidis gene comprising the SEQ ID NO:15 for treating or preventing a condition associated with infection by Neisseria or Gram-negative bacteria | |
JPH10201484A (en) | New ftsl | |
WO2004045499A2 (en) | Identification of actinobacillus actinomycetemcomitans antigens for use in the diagnosis, treatment, and monitoring of periodontal diseases | |
US7785609B1 (en) | Recombinant Haemophilus influenzae adhesin proteins | |
WO2012054879A1 (en) | Compositions and methods for the treatment of septic arthritis, osteomyelitis, and bacteremia | |
US20090226479A1 (en) | Vaccines and their use | |
CA2241023A1 (en) | Novel polynucleotides and polypeptides in pathogenic mycobacteria and their use as diagnostics, vaccines and targets for chemotherapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20020121 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
AX | Request for extension of the european patent |
Free format text: AL;LT;LV;MK;RO;SI |
|
17Q | First examination report despatched |
Effective date: 20040415 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
18W | Application withdrawn |
Effective date: 20040615 |